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This document presents a professional view of evidence-based recommendations around the issues of antiplatelet 
and anticoagulation management in cardiac surgery. It was prepared by the Audit and Guidelines Committee of 
the European Association for Cardio-Thoracic Surgery (EACTS). We review the following topics: evidence for 
aspirin, clopidogrel and warfarin cessation prior to cardiac surgery; perioperative interventions to reduce 
bleeding including the use of aprotinin and tranexamic acid; the use of thromboelastography to guide blood 
product usage; protamine reversal of heparin; the use of factor Vlla to control severe bleeding; anticoagulation 
after mechanical, tissue valve replacement and mitral valve repair; the use of antiplatelets and clopidogrel after 
cardiac surgery to improve graft patency and reduce thromboembolic complications and thromboprophylaxis in 
the postoperative period. This guideline is subject to continuous informal review, and when new evidence 
becomes available. The formal review date will be at 5 years from publication (September 2013). 




Antiplatelet and anticoagulant therapy is a key part of the management of patients undergoing cardiac surgery. 
Most heart operations depend on cardiopulmonary bypass with systemic heparinisation [1] and, postoperatively, 
every patient's thrombotic and haemorrhagic tendency must be carefully managed. 
In recent years, the costs and availability of blood and blood products have changed dramatically. Cardiothoracic 
surgery uses 5% of all donated blood in the UK and 10% of blood in the USA. The cost of donor blood and 
blood products has increased and availability is often critically reduced. In addition to this shortage, there is 
concern over blood-borne infection, including new variant Creutzfeld-Jacob disease [2,3]. For these reasons it is 
paramount that cardiac surgeons make every effort to minimise the usage of blood and blood product usage in 
their patients. 
This guideline will present and summarise the evidence for a range of therapeutic interventions with the aim of 
helping cardiac surgeons to optimise the usage of blood and blood products and to move away from current, 
highly variable practice [4,5] towards a unified, evidence-based approach to the perioperative use of antiplatelet 
and anticoagulant therapy. 
The European Association for Cardio-Thoracic Surgery acknowledges the guideline development work 
performed by other institutions and in particular the work of the European Society for Cardiology (ESC) 
guidelines in the area of management of patients after valve surgery [6,7] and the Society of Thoracic Surgeons 
(STS) guidelines on perioperative blood transfusion and blood conservation [8]. 
2. Scope of the guideline 
This guideline covers antiplatelet and anticoagulation management in relation to cardiac surgery, including 
cardiopulmonary bypass, reversal of heparinisation, assessment and treatment of postoperative coagulopathy and 
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anticoagulation and antiplatelet treatment after discharge from hospital. 
3. Methodology of the guideline 
This guideline comprises several novel aspects of methodology in its derivation. Many guidelines are based on a 
single systematic review and multiple clinical questions are then answered on the basis of the papers found from 
this one review. In contrast, we felt that it was important to perform a full literature review for every single 
question addressed in order to maximise the robustness of the guideline. We used a structured systematic review 
protocol named 'Best Evidence Topics' to construct each review, where the search strategy, results of the search 
and a full appraisal of all papers are published in a structured format. The details of this protocol are described in 
the Interactive Cardiovascular and Thoracic Surgery (ICVTS) [9]. Guidelines often fall short of expectations due 
to a failure to consult those clinicians who are most likely to use them. For this guideline, all the literature 
reviews have already been published in full in the ICVTS. Topics were published online and clinicians were able 
to post comments on them over a 2-month period. These comments were then published together with the full 
paper in the ICVTS and are now available to all readers in full text online at www.icvts.org. 
4.  Levels of evidence and grading of recommendations 
These guidelines assess individual studies according to the recommendations of the Oxford Centre for Evidence 
Based Medicine [9,10]. Briefly, a level 1 paper is a randomised controlled trial (RCT) or a meta-analysis of 
RCTs, a level 2 paper is a cohort study, a level 3 paper is a case-controlled study or a small cohort study, and a 
level 4 paper is an experimental study. The 'b' suffix then implies that the paper is one original article at this level 
and the 'a' suffix implies that the paper is a systematic review or meta-analysis of articles at that level. Once 
recommendations are made, they are graded according to the quality of papers used to come to our conclusion. 
Grade A evidence    based on multiple level 1a or level 1b papers 
Grade B evidence    based on multiple level 2a/2b papers or individual level 1a/1b papers  
Grade C evidence    based on multiple level 3a/3b papers or individual level 2a/2b papers  
Grade D evidence    based on individual level 3a/3b papers or level 4 papers  
Grade E evidence    based on expert consensus in the absence of acceptable papers 
 
5.  Preoperative recommendations 
5.1. Clopidogrel cessation before urgent cardiac surgery 
Evidence was sought for whether clopidogrel should be stopped prior to urgent cardiac surgery. This search is 
fully documented in the ICVTS [11], together with a summary of all identified papers. We found 143 papers and 
all major international guidelines were also included. Of these, 14 presented the best evidence to answer the 
clinical question. 
There are two questions to consider when deciding on the timing of surgery in a patient on clopidogrel. Does 
clopidogrel cause an increase in bleeding complications and their sequelae? Does withholding clopidogrel in 
these high-risk patients expose them to an increase in thrombotic complications prior to surgery? 
In answer to the first question, a meta-analysis of 11 cohort studies in 2004 [12] combined papers providing data 
on patients who either did or did not receive clopidogrel. There was a mean increase in blood loss of 323 ml, a 
six-fold increase in the odds of re-exploration, an increase in adverse events and ventilation time, but no 
difference in hospital length of stay or mortality. It must be remembered that the 11 cohort studies do not take 
into account the fact that the clopidogrel groups are likely to be a higher risk group of patients. 
Since this meta-analysis many additional studies have reported. Kapetanakis et al. [13,14] compared 281 patients 
having clopidogrel before off-pump surgery to 1291 patients who did not have clopidogrel. There were no 
differences in mean blood loss or mortality, but there was a 2—3 times increase in the odds of transfusion and a 
five-fold increase in the odds of re-exploration. In other studies on clopidogrel before CABG, Yende and 
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Wunderink [15] showed an increase in re-exploration rate, Hongo et al. [16] showed an increased re-exploration 
rate and a 50% increase in chest drainage, Englberger et al. [17] showed an increase in re-exploration, red cell 
usage and a doubling in chest drain output, Leong et al. [18] showed a modest increase in chest drainage and an 
increase in blood transfusion but not an increase in re-exploration. Ascione [19] in a 1-year cohort study of 
inpatient referrals found that there was a three-fold increase in the re-exploration rate, a significantly increased 
mortality and more chest drainage. In contrast to these studies Karabulut et al. [20] found no increase in chest 
drainage, re-exploration or red cell transfusion, although the study included 1628 patients of whom only 48 were 
on clopidogrel. Many more similar smaller cohort studies with similar findings are not listed here. Thus in 
answer to the first part of our question, clopidogrel is associated with more blood product usage, a 2—5-fold 
increase in the risk of re-exploration and 30—100% increase in the chest drain blood loss. 
The second question addresses the importance of continuing clopidogrel in these patients. The CURE [21] study 
in 2004 was a double-blind RCT of 12,562 patients who had suffered a non-ST elevation myocardial infarction 
(NSTEMI). It showed that death, myocardial infarction (MI) or stroke occurred in 9.3% of patients randomised 
to clopidogrel and aspirin, compared to 11.4% in the aspirin alone group. In the subgroup of 2072 patients who 
subsequently underwent CABG, the overall benefits of clopidogrel were maintained by the end of the study. In 
addition, there was a trend to fewer complications prior to surgery whilst awaiting the intervention (5.6% vs 
6.7%; number needed to treat (NNT) 90). For patients continuing clopidogrel to within 5 days, preoperatively, 
there was a nonsignificant excess in re-exploration and 9.6% of clopidogrel patients versus 6.3% of placebo 
patients had a major bleeding event. The CURE authors recommend that it is safe for all NSTEMI patients to be 
started on clopidogrel and aspirin on admission, but that clopidogrel should be stopped 5 days before surgery. 
The CREDO trial [22] showed benefits for clopidogrel loading 6 h before percutaneous intervention (PCI) and 
continuing for up to 1 year in a RCT of 2116 patients with no significant difference in bleeding complications, 
although there was a high incidence of major bleeding in the subset of patients proceeding to CABG. 
The CLARITY-TIMI-28 [23] trial randomised 3491 patients who had suffered MI within 12 h to clopidogrel or 
placebo. This showed a 7% absolute risk reduction for death, MI or stroke with clopidogrel. A small group of 
136 patients who proceeded to CABG did not have an excess risk of bleeding although neither blood loss nor 
blood product usage were reported in detail. The ACC/AHA guidelines [24] of 2002 on the management of 
NSTEMI and unstable angina recommend immediate administration of clopidogrel if PCI is planned. They 
furthermore recommend cessation of clopidogrel for 5—7 days prior to surgery, giving this a grade B level of 
evidence. 
The PCI-CURE study [25] provides important data when considering withholding clopidogrel for patients before 
CABG: 1313 patients received clopidogrel prior to PCI with 1345 placebo controls in this double-blind RCT The 
mean wait for PCI was 6 days and the incidence of MI while awaiting intervention was 5.1 % in the placebo 
group but only 3.6% in the clopidogrel group (p = 0.04, NNT 66 to prevent an MI pre PCI). 
Thus there is a clear benefit in commencing clopidogrel for patients suffering an Ml, NSTEMI or shortly to 
require PCI, and this therapy should not be withheld even if a possible future CABG is possible. However, once 
it is decided that CABG is required, the ACC/AHA guidelines [24], the STS guidelines [8], the meta-analysis 
and multiple cohort studies would recommend cessation of clopidogrel for 5—7 days. The CURE study and its 
sub-analyses show that cessation of clopidogrel in these patients for this time period is associated with a 1% 
increase in the risk of MI. 
Recommendation: 
Patients who need urgent cardiac surgery should stop clopidogrel 5—7 days before surgery if their clinical 
condition allows. The benefit in reducing perioperative blood loss, risk of re-exploration and blood product 
usage is at the expense of a 1% increase in the risk of myocardial infarction while awaiting surgery. (Grade B 
recommendation based on individual level 1a and 1b studies) 
5.2. Cessation of warfarin and aspirin before cardiac surgery 
Several guidelines address the issue of cessation of warfarin and aspirin before non-cardiac surgery. These 
guidelines can also be applied to cardiac surgical patients. 
The American Heart Association [26,27] recommends that in patients at a relatively low risk of thrombosis such 
as those with a bileaflet mechanical aortic valve with no additional risk factors, warfarin should be stopped         
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48—72 h prior to surgery so that the INR drops to below 1.5 and heparin is unnecessary prior to surgery. In 
patients at high risk of thrombosis, defined as those with a mechanical mitral valve replacement or a mechanical 
aortic valve replacement with additional risk factors, therapeutic doses of intravenous heparin should be started 
when the INR falls below 2.0 (typically 48 h before surgery), stopped 4—6 h before the procedure, restarted as 
early after surgery as bleeding stability allows, and continued until the INR is again therapeutic with warfarin 
therapy (level of evidence B). 
The British Society of Haematology [28,29] recommends that warfarin be stopped at least 3 days before surgery, 
with higher risk patients such as those with a mechanical valve receiving intravenous heparin when the INR falls 
below the therapeutic range. 
The American College of Chest Physicians [30] documents the results of pertinent studies but states: 'until 
clinical trials that specifically target the perioperative management of patients requiring vitamin K antagonist 
anticoagulation before surgical procedures are performed, treatment of such patients will remain controversial 
and we are not making a recommendation.' 
With regard to aspirin cessation before cardiac surgery, the ACC/AHA guidelines [31] recommend cessation of 
aspirin for 7—10 days before elective CABG, due to the increased risk for transfusion, prolonged wound closure 
time, and a fourfold increase in early re-operation for bleeding [32]. This does not apply to patients who may 
have an acute coronary syndrome where the benefits may outweigh these risks. The STS also recommends 
cessation of aspirin in purely elective patients without acute coronary syndromes 2—3 days before surgery in the 
expectation that rates of blood transfusion will be reduced. 
Recommendation: 
Patients on warfarin before cardiac surgery should be managed in a similar manner to those undergoing major 
non-cardiac surgery. Warfarin should be stopped 2—4 days before surgery and patients at higher risk of 
thrombosis should receive intravenous heparin once the INR becomes sub-therapeutic. (Grade B 
recommendation based on multiple level 2a and 2b studies) Patients should stop aspirin 2 — 10 days before 
elective cardiac surgery in order to reduce perioperative blood loss. Patients undergoing urgent cardiac surgery 
with an acute coronary syndrome should continue aspirin up to the day of surgery. 
(Grade B recommendation based on multiple level 2a and 2b studies) 
6. Perioperative interventions to reduce bleeding and blood product usage 
6.1. Aprotinin 
Evidence was sought for the efficacy of aprotinin in reducing perioperative bleeding and whether there are 
adverse side effects that may affect renal function, graft patency or mortality after CABG. A search for the 
evidence surrounding the effect of graft patency is fully documented in the ICVTS [33], together with a 
summary of all identified papers. 
In addition the STS provide a recent review in this area together with recommendations [8], and more recently a 
meta-analysis has been published in Circulation in 2007 [34] in the light of papers by Mangano et al. [35,36]. 
However on the 5th of November 2007, the FDA suspended aprotinin in the light of the BART study [37] being 
stopped early due to safety concerns [38] and the MRHA have since suspended the licensed use of aprotinin in 
the UK from the 7th of December 2007 (www.mrha.gov.uk). 
The IMAGE study [39] of 870 patients in 13 centres found a higher occlusion rate of saphenous grafts after 
aprotinin use, with 15% of patients having an occlusion in the aprotinin group, compared to 11% in the control 
group. Although the study was an RCT, the authors performed a risk adjustment and concluded that after 
allowing for risk factors there was no difference in the occlusion rate. In another study, Laub et al. [40] also 
found a 30% occlusion rate in the aprotinin group and none in the control group but the study numbers were 
small. In the remaining studies reporting vein graft patency no significant differences were found although 
Lemmer et al. [41], Bidstrup et al. [42] and van der Meer et al. [43] found non-significant trends towards worse 
patency rates with aprotinin. 
Due to the varying findings of these studies we combined their data by meta-analysis using a random effects 
model. We found that a significant increase in the odds of occlusion was 1.52 [1.13—2.03]. We therefore 
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conclude that there is a small but significant increase in graft occlusion in patients undergoing CABG with 
aprotinin. 
Of note, the amount of blood loss and blood product usage is significantly lower in the patients receiving full 
dose aprotinin in all the studies. The Cochrane review combined data from 61 studies and found a 30% reduction 
in blood transfusion, less blood drainage and a significantly lower incidence of re-operation due to bleeding [44]. 
The 2007 STS guidelines [8] state that high-dose aprotinin is indicated to reduce the number of patients requiring 
transfusion, reduce total blood loss and to limit re-exploration. They give this a grade A level of evidence 
recommendation but warn that high dose aprotinin may increase the incidence of renal dysfunction. They also 
recommend that low dose aprotinin reduces blood loss and blood transfusion with the same grading of the 
evidence. Of note the Food and Drug Administration also issued a safety alert suggesting that only patients for 
whom the benefits of aprotinin outweighed the risks in terms of renal dysfunction and hypersensitivity should 
receive the drug (www.fda.gov). This was based on a meta-analysis and update in 2006 of 31 studies in this area. 
They found that the incidence of renal dysfunction was 8.4% in patients receiving placebo and 12.9% in those 
receiving aprotinin. However, the incidence of renal failure was not significantly different [45,46]. The 
metaanalysis update [45] has now been fully published by Brown et al. in Circulation [34] after the FDA alert, 
comparing aprotinin, tranexamic acid and ε-aminocaproic acid. They identified 138 randomised trials from 
which they extracted data on eight clinical outcomes. Aprotinin significantly reduced the incidence of re-
exploration (RR 0.49). High dose aprotinin reduced total blood loss by mean 184 ml (95% CI —256 to—112) 
compared to tranexamic acid but there was no significant difference of low dose aprotinin compared to 
tranexamic acid. There were no differences between these three agents in terms of mortality, stroke, myocardial 
infarction or renal failure but high dose aprotinin significantly increased the risk of renal dysfunction from 8.4% 
to 12.9% which is a number indicating harm to 22 patients. Renal dysfunction was defined as an increase of 
more than 0.5 mg/ dl in serum creatinine. Data were not extracted on vein graft patency in this study. 
Major concerns regarding aprotinin were first highlighted by Mangano et al. [35,36] who reported significantly 
increased adverse outcomes in 1295 patients who received aprotinin within a cohort of 4374 patients undergoing 
'primary' (CABG only) or 'complex' (all other) surgery. Using logistic regression analysis and propensity scoring 
techniques they reported that the risk of stroke was increased by 181% and the risk of MI by 55% in 'primary' 
surgery, and the incidence of renal failure doubled in both 'primary' and 'complex' surgery. They also noted dose-
response aprotinin effects and commented that as other antifibrinolytics such as tranexamic acid and                        
ε-aminocaproic acid had similar blood-sparing benefits without adverse effects, continued use of aprotinin was 
'not prudent'. Whilst this study has several weaknesses, including a risk of bias from systemic sampling across 
multiple institutions with inherently embedded practices, and higher risk factors for some adverse outcomes 
within the aprotinin group, it has resulted in considerable debate and may lead to some reappraisal of the role of 
aprotinin, particularly in uncomplicated 'primary' surgery. 
An independently funded, randomised clinical trial with three study groups (aprotinin, tranexamic acid and               
ε-aminocaproic acid) was set up in Canada. The BART study aimed to enrol 2970 patients specifically to answer 
many of the safety concerns raised by Mangano et al. [36], the FDA and others [37,47]. However on the 19th of 
October 2007, this study was stopped early due to an increase in mortality in the aprotinin group. The Data 
Safety Monitoring Board reported that: 
1.  The 30-day mortality in the aprotinin group had nearly reached conventional statistical significance at the 
interim analysis, when compared to either ε-aminocaproic acid or tranexamic acid. 
2.  A trend toward increased mortality in the aprotinin group had been observed throughout the study. 
3.  The use of aprotinin was associated with less serious bleeding than either of the comparator drugs; however, 
more deaths due to haemorrhage had been observed among patients receiving aprotinin. 
4. The DSMB concluded that continued enrolment of patients into the aprotinin group was unlikely to 
significantly change the study findings. 
This announcement is by the FDA [38] and it is likely that further announcements will be made in the near future 
as the BART data is further analysed and then published. 
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Recommendation: 
Aprotinin reduces blood loss and the need for blood transfusion in cardiac surgery; however there is a proven 
association with postoperative renal dysfunction and a probable association with increased mortality after a large 
randomised controlled trial has been stopped early due to these concerns. Routine use of aprotinin in cardiac 
surgery is not recommended, but use in patients at particularly high risk of bleeding may be still be justified. 
This is the subject of current FDA and MRHA review, and these recommendations may change in the near 
future. 
(Grade A recommendation based on level 1a and 1b studies) 
6.2. Tranexamic acid to reduce perioperative bleeding 
Evidence was sought for the efficacy of tranexamic acid in reducing perioperative bleeding and whether it may 
adversely affect graft patency after CABG. This search is fully documented in the ICVTS [48] together with a 
summary of all identified papers. We found 334 papers using the presented search strategy. A subsequent meta-
analysis and a guideline were added on updating. From these papers, 14 represented the best evidence on this 
topic. 
Two recent meta-analyses, 1 cohort study and 10 RCTs documented studies comparing tranexamic acid to either 
aprotinin or placebo with documentation of thrombotic complications. The meta-analysis by Fremes [49] in 1994 
found only two papers on tranexamic acid and concluded that either ε-aminocaproic acid or tranexamic acid 
reduced bleeding by 30% with no increase in perioperative myocardial infarction. 
The 2001 Cochrane review by Henry et al. [44] found 61 trials of aprotinin and 18 trials of tranexamic acid and 
found an absolute risk reduction in red blood cell transfusion of 20% with aprotinin and 17% with tranexamic 
acid with no difference in transfusion rates. They conclude that the evidence is much weaker for tranexamic acid 
but it may well be as effective as aprotinin. 
The only study that highlighted anxiety over the safety of tranexamic acid was the cohort study by Ovrum et al. 
[50] published in 1993. Ovrum routinely used tranexamic acid until a patient had an acute thrombosis of all her 
grafts and adjacent native coronaries. He stopped using it and analysed the results of his next 100 patients 
compared to the previous 100. There had been five MIs with tranexamic acid but only one MI without 
tranexamic acid, which was not statistically significant. This is a retrospective, single-surgeon study, with 
potential bias introduced by the change in practice. 
The largest RCT was by Casati et al. [51] who compared aprotinin to tranexamic acid in 1040 primary elective 
CABG patients. There was no difference in survival, bleeding, reoperation for bleeding, transfusion, 
perioperative MI, early re-operation for ischaemia, pulmonary embolism (PE) or neurological dysfunction 
although the number of events in each of these categories was small. The conclusion was that tranexamic acid 
was clinically as effective as aprotinin at a fraction of the cost. 
Five RCTs compared tranexamic acid to placebo. Four of the five showed a reduction in bleeding rates. None of 
the studies investigated graft patency, but other outcome measures such as MI, PE, and neurological dysfunction 
were reported, and no concerns were raised about the safety of tranexamic acid. It is important to note that the 
incidence of thrombotic complications is low and, with the largest study having fewer than 150 patients, none of 
these studies are sufficiently powered to exclude the possibility of increased thrombotic complications. Thus it is 
clear that tranexamic acid reduces the incidence of postoperative bleeding, and only one cohort study has raised 
any concern over its safety in terms of thrombotic complications. No study has looked directly at vein graft 
patency after tranexamic acid. The STS guidelines state that tranexamic acid is indicated to reduce the rate of 
blood transfusion but that it is slightly less potent than full dose aprotinin and its safety profile is less well 
studied [8]. 
Recommendation: 
Tranexamic acid reduces blood loss, requirement for blood transfusion, and the risk of reoperation for bleeding. 
(Grade A recommendation based on level 1a and 1b studies) 
No study has yet looked directly at vein graft patency with tranexamic acid, but equally no randomised studies 
have raised concerns over its safety. 
(Grade B recommendation based on individual level 1b studies) 
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6.3. Topical tranexamic acid to reduce perioperative bleeding 
Evidence was sought for the efficacy of topical tranexamic acid in reducing perioperative bleeding. This search 
is fully documented in the ICVTS [52] together with a summary of all identified papers. We found 511 papers 
using the presented search strategy. From these papers only one represented the best evidence on this topic. One 
abstract has not yet been published in full and was thus excluded [53]. Two additional RCTs were published 
after our search had been conducted [54,55]. Several other papers deal with the use of topical tranexamic acid 
after bladder, dental and gynaecological surgery but are probably of doubtful relevance to cardiac surgery. The 
STS guidelines on blood conservation do not consider this topic [8]. 
In a double-blind RCT, De Bonis et al. [56] randomised 40 consecutive patients undergoing CABG to topical 
tranexamic acid or placebo. One gram of tranexamic acid was added to 100 ml of normal saline and poured into 
the sternotomy wound prior to closure. The mediastinal drains were clamped during closure, and the clamps 
were only removed after the operation had been completed. Placebo patients received 100 ml of normal saline. 
There was a 36% reduction in bleeding at 3 h and a 25% reduction at 24 h in the tranexamic acid group. 
However, the absolute differences were small with a mean blood loss of 485 ml in the tranexamic acid group and 
641 ml in the placebo group. In addition, no reduction in the use of blood products was demonstrated. The 
second more recent study was by Abdul-Azm and Abdullah in 2006 [54] who randomised 100 patients to receive 
2 g of tranexamic acid in 100 ml of saline into the pericardium prior to closure, or saline alone. Bleeding was 
reduced from a mean of 1208 ml to 733 ml, which was highly significant, and blood transfusion usage was also 
reduced. The third RCT by Yasim et al. [55] which was also the smallest, randomised 10 patients to topical 
aprotinin, topical tranexamic acid or controls. Mean blood loss for the aprotinin group was 384 ml, for 
tranexamic acid 393 ml, and for controls 502 ml. This was not statistically significant due to the small sample 
size. 
In summary, one RCT demonstrates a small reduction in blood loss, a second more recent study demonstrates a 
larger reduction and a third study showed a non-significant trend towards reduction. Further RCTs should be 
performed (and could very easily be set up and conducted) prior to any reliance on topical tranexamic acid as a 
strategy to reduce postoperative bleeding. 
Recommendation: 
Topical tranexamic acid may reduce postoperative bleeding after cardiac surgery. Routine use is probably safe 
and may be effective, but further RCTs should be performed.(Grade B recommendation based on two level 1b 
studies) 
6.4. Hepcon® for minimisation of blood and blood product usage 
Evidence was sought for whether use of the Hepcon point-of-care coagulation monitor to optimise and monitor 
heparin and protamine dosage for cardiopulmonary bypass could decrease bleeding and blood and blood product 
requirements in adult patients undergoing cardiac surgery. This search is fully documented in the ICVTS (Aziz 
et al. [57]) together with a summary of all identified papers. 
Altogether 680 papers were identified on Medline, and 879 on Embase using the reported search strategy.          
Two further relevant papers were found by hand searching of reference lists. Fourteen papers represented the 
best evidence on the topic. 
Hepcon calculates heparin doses required for cardiopulmonary bypass by establishing the heparin dose response, 
measures heparin concentrations during bypass and calculates protamine doses based on residual heparin. 
Raymond et al. [58] validated it by comparing it to a lab-based anti-Xa assay which demonstrated that heparin 
concentration is a better guide than activated clotting time (ACT). Murray et al. found similar correlations [59]. 
A number of studies report that Hepcon use results in higher total heparin doses and lower protamine doses than 
conventional management [60—66]. This may be due to less coagulation system activation during 
cardiopulmonary bypass. Several studies have confirmed decreased coagulation system and inflammatory 
marker activation using Hepcon-guided therapy. Ohata et al. [67] demonstrated significantly lower interleukin-8 
levels after CPB and protamine, and Shigeta et al. [61] noted that lower Hepcon-guided protamine doses were 
associated with better platelet function. Koster et al. [68] found that anti-Xa levels were significantly higher, and 
thrombin-antithrombin complexes, D-dimers, and neutrophil esterase levels lower in the Hepcon-managed 
group. In a subgroup of a 1995 study, Despotis et al. found significantly better preservation of clotting factors V 
and VIII, antithrombin III, and fibrinogen in the Hepcon group prior to protamine administration [62]. Several 
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inflammatory markers were also significantly lower in the Hepcon group. They also found that patients who bled 
excessively had higher D-dimer levels and plasmin-antiplas-min complexes and lower factor V, X and platelet 
counts before protamine administration [63]. The clinical impact of these findings remains unclear. Neither 
Yamanishi nor Sakurada found excessive bleeding in their Hepcon groups despite larger heparin and smaller 
protamine doses [60,65]. Shigeta et al. similarly observed no difference in bleeding although Hepcon 
management improved platelet preservation [61]. In a larger study investigating haemostatic-inflammatory 
activation, Koster reported no difference related to Hepcon in blood loss or blood product requirement [68]. 
Ohata found less blood transfusion when protamine was given according to Hepcon-measured heparin 
concentration [67]. Despotis found that Hepcon use was associated with significantly less bleeding in the first 4 
h, more rapid chest closure, and decreased requirement for 'haemostatic intervention' [62]. Whilst red cell use 
just failed to reach significance, use of fresh frozen plasma (FFP), platelets and cryoprecipitate requirements was 
significantly less in the Hepcon group. More recently, Avidan compared Hepcon and other point-of-care tests to 
laboratory tests. Bleeding was similar, but blood and blood component requirements were less in point-of-care 
tests [69]. Incontrast, Beholz et al. reported more bleeding using Hepcon leading to increased autologous 
transfusion requirement but no additional blood products [66], and a retrospective study by Newsome compared 
Hepcon and Rapidpoint® coagulation monitors and reported more bleeding and requirement for both FFP and 
red cells in the Hepcon group, which was attributed to the larger heparin dose [64]. Other protamine titration 
monitors are available. The Hemocron RxDx® device quantifies heparin and protamine doses on a patient-
specific basis. Its use also leads to larger heparin and smaller protamine doses but Shore-Lesserson demonstrated 
no impact on bleeding or blood, FFP or platelet transfusion requirement [70]. The STS guidelines [8] consider 
this subject and conclude that it is not unreasonable to use methods to lower the heparin to protamine ratio at the 
end of CPB, giving this a grade B level of evidence. 
Recommendation: 
Hepcon monitoring is associated with higher heparin and lower protamine doses and may decrease activation of 
the coagulation and inflammatory cascades. Some studies have shown this may decrease postoperative bleeding 
and blood product requirement. Its routine use is not unreasonable but larger trials are needed to investigate this 
further. (Grade B recommendation based on level 1b and 2b studies) 
7. Postoperative interventions to reduce bleeding and blood product usage 
7.1. Thromboelastography to guide blood and blood product usage 
Evidence was sought whether use of thromboelastography (TEG) could predict and decrease bleeding and blood 
and blood product requirements in adult patients undergoing cardiac surgery. This search is fully documented in 
the ICVTS [71], together with a summary of all identified papers. We found 170 papers using the reported 
search strategy of which 14 represented the best evidence on the topic. 
Abnormal TEG data may predict patients who will bleed. Speiss et al. [72] found that TEG correlated well with 
ACTand coagulation profiles and whilst no coagulation test was consistently specific, the TEG was the most 
accurate predictor of bleeding. Ereth et al. [73] studied a 'platelet-activated clotting test' (PACT®), ACT, clotting 
studies and TEG. PACT sensitivity and specificity was comparable to conventional coagulation tests in 
predicting blood loss but TEG was superior. Essell et al. [74] found that the bleeding time and platelet count had 
similar sensitivity but less specificity when compared to TEG. Patients with an abnormal TEG were at increased 
risk of bleeding and excessive bleeding in the face of a normal TEG implied a surgical cause. Ti et al. [75] found 
moderate correlation between TEG parameters, total blood loss and requirements for FFP or platelets in bleeders. 
Other studies did not find the TEG to be a useful predictor of blood loss. Nuttall et al. [76] reported that TEG 
values had a low sensitivity and specificity in predicting bleeders. Dorman et al. [77] compared preoperative 
coagulation screens to ACT and TEG as predictors of blood loss but found no significant relationship between 
any TEG variable and blood losses. 
A number of studies have used TEG to guide transfusion management. Avidan et al. [69] compared TEG to a 
laboratory-based algorithm and concluded that despite similar bloodloss, blood and blood product usage were 
significantly greater in the laboratory group. Speiss et al. [78] analysed 1079 patients before and after the 
introduction of TEG as part of an overall transfusion management strategy and found significantly less re-
exploration and less use of all blood and blood components except cryoprecipitate. However, this study may 
have been biased by the Hawthorne effect. (The improvement in results that may be found just by monitoring a 
process.) 
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Two RCTs have been performed. Shore-Lesserson et al. [79] compared TEG-based and conventional protocols 
to manage postoperative bleeding. Whilst there was no significant difference in blood loss between the groups, 
blood and blood component therapy was significantly less in the TEG than the conventional group. However the 
TEG protocol did have more options than the conventional protocol and also partly depended on laboratory tests. 
In addition, blood products were ordered on the basis of a TEG taken at rewarming on cardiopulmonary bypass 
and given in the presence of continued bleeding following protamine, whereas the conventional group awaited 
post-protamine tests to dictate intervention. This inevitably meant earlier intervention in the TEG group. Royston 
and Von Kier [80] studied 60 patients who had undergone complex surgery comparing their actual blood and 
blood product use to a predicted usage derived from a TEG-based algorithm. 'Predicted' blood and blood product 
transfusion was significantly less than 'actual' transfusion. They subsequently used this algorithm comparing it to 
conventional management in a further 60 patients. Again they demonstrated significantly less blood and blood 
product usage in the TEG-based group compared to the conventional 'clinician-directed' group with no excessive 
mediastinal bleeding. However this study was designed to identify TEG evidence of coagulation before physical 
evidence of microvascular bleeding and the authors acknowledge the fact that their protocol allowed much 
earlier intervention in the active than the control limb. 
A recent review by Samama and Ozier [81] has raised concerns that TEG remains an unvalidated technique 
which fails to achieve the stringent standard quality control procedures essential in lab-based tests, citing absence 
of a formal standard operating procedure taking into account factors such as gender and pregnancy differences, 
stability of blood samples, and sampling site. There is also no standardised technique and multiple modifications 
have been described. Several studies acknowledge that TEG facilitates earlier intervention than standard 
coagulation tests [69,79,80] thus making true comparisons difficult. Samama and Ozier conclude by suggesting 
that extended collaborative studies involving haematologists are required to evaluate and validate TEG further 
[81]. 
Recommendation: 
Thromboelastography may be used to guide transfusion in the postoperative period and studies have 
demonstrated a reduction in blood and blood product usage if used in conjunction with a treatment algorithm. 
Further studies are required before thromboelastography can be recommended as the standard of care for 
postoperative transfusion management. (Grade B recommendation based on level 2b studies) 
7.2. Is there a protamine anticoagulant effect after cardiac surgery? 
Evidence was sought as to whether large doses of protamine cause increased bleeding after cardiac surgery. This 
search is fully documented in the ICVTS [82] together with a summary of all identified papers. We found 268 
papers using the reported search, of which five presented the best evidence to answer the clinical question. 
Studies from Carr and Carr [83] and Moshizuki et al. [84] provide convincing evidence that when the ratio of 
protamine (in mg/l) to heparin (in unit/ml) is above 5:1, platelet aggregation and function are impaired. In 
addition, Moshizuki et al. demonstrated that at ratios above 2.6:1 the ACT significantly increases. Interestingly, 
Butterworth et al. [85] showed that protamine is eliminated in 20—30 min in physiological situations and 
Gundry et al. [86] provided evidence that prolonged ACT correlates poorly with the presence of free heparin. An 
indication of how an ACT-based protocol may affect bleeding is given by Jobes et al. [87] who showed that 
using protamine response tests to guide dosage reduced mediastinal blood loss by 50%. The STS guidelines [8] 
state that it is not unreasonable to use protamine titration or empiric low-dose regimens to reduce bleeding and 
blood transfusion requirements although they do not address the possibility of rebound bleeding at higher doses 
of protamine (level of evidence B). 
Recommendation: 
Excessive doses of protamine can impair platelet function and increase bleeding. These effects have only been 
demonstrated when the ratio of protamine to heparin is greater than 2.6:1. 
(Grade B recommendation based on level 1b and 2b studies) 
7.3. Recombinant factor VIIa for intractable bleeding after cardiac surgery 
Evidence was sought for the role of recombinant activated factor VII for intractable bleeding after cardiac 
surgery. This search is fully documented in the ICVTS (Tanos and Dunning [88]) together with a summary of all 
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identified papers. Altogether 129 papers were identified using the reported search strategy of which 13 
represented the best evidence on the topic. On updating, a recent review in the New England Journal of Medicine 
was added [47]. 
Roberts et al. in 2004 [89] published a review of the current use of factor VIIa across all specialties. Over 
400,000 instances have been recorded, mostly in haemophiliacs, and the risk of serious adverse events was 
estimated as less than 1%. The risk of non-serious adverse events was estimated as 8—13%. The usual dose was 
90 mcg/kg, but larger doses of 320 mcg/kg have also been recorded without major adverse effects. 
In 2005, Levi et al. [90] performed a systematic review of the efficacy and safety of recombinant factor VIIa. 
They identified 28 clinical trials and 300 other case reports and series including 1854 patients. In haemophiliacs, 
efficacy over 90% has been demonstrated at a dose of  90 mcg/kg in 156 articles. If bleeding continues, an 
infusion of 16.5 mcg/kg h may also be started. In a further 37 patients with severe bleeding they reported a 60% 
efficacy in bleeding reduction. Boffard et al. [91] performed an RCTof 301 patients with severe blunt trauma 
showing significant reduction in RBC use, a 5% reduction in mortality (NS) and a trend to less organ 
dysfunction. The risk of adverse thromboembolic events in non-haemophiliacs was estimated at 1.4%. Thus 
factor VIIa has been well tested and its safety established in haemophiliacs and non-cardiac surgical patients. 
The only RCT in high-risk cardiac surgical patients was by Diprose et al. [92] in which 20 patients were 
randomised to receive factor VIIa or placebo after reversal of heparin. Mean drainage was halved (630 ml down 
to 330 ml) and total blood product use was 13 units in the trial arm compared to 105 in the placebo arm. In a 
second paper, the authors reported dramatic reductions in blood loss in 17 patients when factor VIIa was used as 
rescue treatment in patients with massive blood loss after cardiac surgery [93]. 
Karkouti et al. [94] reported 51 patients with intractable bleeding after cardiac surgery who received between 35 
and 70 mcg/kg of factor VIIa after blood loss exceeded 2000 ml despite platelets and FFP. They reported a 
significant reduction in blood loss and in the use of blood products. Four patients had a stroke, but one had loose 
atheroma in the aortic arch and two had a significant period of cerebral hypoperfusion. 
Aggarwal et al. [95] reported the results of 24 patients who received 90 mcg/kg of factor VIIa for intractable 
bleeding after cardiac surgery. There was a significantly lower requirement for blood and blood products after 
administration compared to before administration. Only six patients survived to discharge and one patient 
suffered a subclavian vein thrombosis in association with central venous line. Von Heymann et al. reported 24 
patients who had factor VIIa for intractable bleeding after cardiac surgery [96]. They also identified a matched 
paired retrospective cohort for comparison. No thrombotic complications were seen and blood loss was reduced 
to less than 100ml/h in 18 of 24 patients. Interestingly, in the control group where routine treatment had been 
given, a similar reduction in blood loss was observed in 17 patients. 
Hyllner et al. [97] reported 24 cases of factor VIIa use in intractable bleeding after cardiac surgery. There was a 
significant reduction in blood loss, no deaths from bleeding and no thrombotic complications. In the remaining 
studies Bishop et al. [98], Vanek et al. [99], Halkos et al. [100], Al Douri et al. [101] and DiDomenico et al. 
[102] reported between 2 and 12 cases of the use of factor VIIa for intractable bleeding after cardiac surgery. 
DiDomenico observed one fatal case of ECMO circuit and cardiac thrombosis and one of possible tamponade by 
mediastinal thrombus, but no other complications were documented in the other studies. 
A review in the New England Journal of Medicine advocated factor VIIa for intractable bleeding in cardiac 
surgery although it voiced some reservations about the proven safety profile with regard to thrombotic 
complications and called for more studies to be performed [47]. 
The STS guidelines [8] state that it is not unreasonable to use factor VIIa for the management of non-surgical 
bleeding unresponsive to routine haemostatic therapy (level of evidence B). 
Factor VIIa has proven efficacy and safety in over 400,000 uses worldwide outside the cardiothoracic surgical 
arena, mostly in haemophiliacs, with around 1% risk of serious thrombotic complications. In cardiac surgery, 
there have been more than 160 reports of its use for intractable bleeding and the rate of serious thrombotic 
complication is again around 1—2%. 
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Recommendation: 
After cardiac surgery, intractable bleeding refractory to conventional haemostatic intervention may be treated 
successfully with factor VIIa, but there is a small risk of serious or fatal thrombotic complications. (Grade C 
recommendation based on level 2b, 3b and level 4 studies) 
8. Anticoagulation after valve replacement 
There are several well-conducted and up-to-date guidelines on this subject. For this reason, we elected not to 
perform our own literature review. Guidelines in this area include the European Society of Cardiology (ESC) 
valve guidelines of 2005 [6] the American College of Chest Physicians (ACCP) valve guidelines 2004 [30], The 
American Heart Association/American College of Cardiology (AHA/ ACC) guidelines 2006 [27], the British 
Society of Haematology guidelines [28], the Canadian Cardiovascular Society [103] and the Scottish 
Intercollegiate Guidelines Network (SIGN) guidelines [104]. The findings of these guidelines are summarised in 
Table 1 for aortic valve replacements (AVR) and Table 2 for mitral valve replacements (MVR). 
Mechanical valves require anticoagulation. Lack of anticoagulation results in an embolism or valve thrombosis 
rate of up to 12% per year for aortic valves and 22% per year for mitral valves [105]. With anticoagulation, this 
risk will be reduced to around 1—4% per year. The risk is higher for patients with a mechanical valve in the 
mitral position and for patients with additional risk factors such as atrial fibrillation (AF), poor left ventricular 
function, or a history of thromboembolism or hypercoagulability [30]. 
In 2005, the European Society of Cardiology (ESC) updated the 1995 guidelines and provided a comprehensive 
document for the management of anticoagulation for patients with mechanical valve replacements [6,106]. In 
this document the ESC acknowledges the increasing risk of thromboembolism due to both valve-related and 
patient-related factors. Thus a patient in sinus rhythm with good left ventricular function receiving a St Jude 
AVR would have a target INR of 2.5 but a patient in atrial fibrillation with a Bjork-Shiley valve would be given 
a target INR of 3.5. 
 
Table 1 : Summary of guidelines for INR for mechanical aortic valve 
 Mechanical aortic valve with no risk factors Mechanical aortic valve with risk factors 
ESC guidelines [6] Low-risk valve: INR 2.5 Low-risk valve: INR 3.0 
 Medium-risk valve: INR 3.0 Medium-risk valve: INR 3.5 
 High-risk valve: INR 3.5 High-risk valve: INR 4.0 
 Low risk: Medtronic Hall, St Jude (not 
Silzone), Carbomedics 
 Medium risk: bileaflet valves with 
insufficient data, Bjork-Shiley 
 High risk: Lillehei-Kaster, Omniscience, 
Starr-Edwards 
Atrial fibrillation, left atrium >50 mm, mitral valve 
gradient, ejection fraction <35%, spontaneous echo 
contrast, additional valve replacements, 
hypercoagulability, history of thromboembolism 
 
 
AHA/ACC guidelines [27] INR 2.0-3.0 INR 2.5-3.5  
 (INR 2.5-3.5 for first 3 months) Atrial fibrillation, left ventricular dysfunction, 
previous thromboembolism, hypercoagulable 
condition, tilting disk and Starr-Edwards valves 
ACCP guidelines [30] INR 2.0-3.0  INR 2.5-3.5  
 St. Jude, Carbomedics, Medtronic-Hall 
tilting disk 
AF, myocardial infarction, left atrial enlargement, 
endocardial damage, systemic embolism and low 
ejection fraction, caged ball or caged disk valve 
BSH guidelines [28] INR 2.5 INR 3.0  
  Tilting disc 
 Bileaflet valves INR 3.5 
  Caged ball or caged disk 
SIGN guidelines [104] INR 3.0 (range 2.5-3.5)  INR 3.5 (range 3.0-4.5)  
 Second generation valves such as St Jude, 
Medtronic-Hall, Monostrut 
Starr-Edwards, Bjork-Shiley standard 
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Both the American Heart Association and the American College of Cardiology guidelines provide similar 
recommendations, although their levels of stratification according to patient-related and valve-related factors are 
generally less well defined. 
Recommendation: 
We recommend that European cardiothoracic surgeons fol low the guidelines provided by the European Society 
of Cardiology. These guidelines are detailed, up to date and will continue to be updated in the future. 
 
Table 2 : Summary of guidelines for INR for mechanical mitral valve 
ESC guidelines [6] Low-risk valves: INR 3.0 
 Medium-risk valves: INR 3.5 
 High-risk valves: INR 4.0 
 Low risk: Medtronic Hall, St Jude (not Silzone), Carbomedics 
 Medium risk: bileaflet valves with insufficient data, Bjork-Shiley 
 High risk: Lillehei-Kaster, Omniscience, Starr-Edwards 
AHA/ACC guidelines [27] INR 2.5-3.5 
ACCP guidelines [30] INR 2.5-3.5 
BSH guidelines [28] Bileaflet and tilting disc valves: INR 3.0  
Caged ball or caged disc valves: INR 3.5 
SIGN guidelines [104] Second generation valves (St Jude, Medtronic, Monostrut): INR 3.0 
(range 2.5-3.5) Starr-Edwards, Bjork-Shiley standard: INR 3.5 (range 
3.0-4.5) 
 
8.1. Warfarin after tissue valve replacement 
Evidence was sought for whether warfarin should be routinely prescribed for the first 3 months after a tissue 
valve replacement either in the aortic or mitral position. This search is fully documented in the ICVTS [107] 
together with a summary of all identified papers. Altogether 620 papers were identified using the search. In 
addition, all major international guidelines were included and a recent high-quality review [108]. Sixteen papers 
presented the best evidence to answer the clinical question. 
The most recent guidelines from the European Society of Cardiology in 2005 [6] recommend that, due to the 
absence of studies showing the safety of omitting anticoagulation for 3 months after bioprosthesis implantation, 
warfarin should be given at INR of 2.5 or 3.0 in higher risk patients. The ACCP guidelines from 2001 and 
updated in 2004 [30,109] recommend warfarin for 3 months for mitral bioprostheses, giving this a grade 1C + 
recommendation, and in the aortic position they also recommend warfarin but as a grade 2C recommendation, 
with an INR of 2.0—3.0 (grade 1C). The ACC/AHA guidelines published in 1998 [110,111 ] and updated in 
2006 [27] stated that the greatest thromboembolic risk is in the immediate postoperative days and recommend 
heparin followed by warfarin for 3 months (class IIa based on grade C evidence). Thereafter, if the patient has no 
risk factors, warfarin may be stopped (class I). 
In 1998 The Scottish Intercollegiate Guideline Network [104] recommended warfarin for 3 months for an aortic 
bioprosthesis (grade C) and for 3—6 months for a mitral bioprosthesis (grade A). They recommend an INR 
target of 2-3. 
The British Society of Haematology produced guidelines in 1998 (unchanged in an update in 2005) [29] 
recommending that patients with mitral bioprostheses receive anticoagulation for 3—6 months. They did not 
recommend warfarin for aortic bioprostheses although they acknowledged that some institutions did. 
Most guidelines advise 3 months of warfarin therapy, yet two large surveys have shown that this is not routine 
practice for aortic valves. In the 2004 survey by CTSnet (www.ctsnet.org) [5] with 726 respondents worldwide, 
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while 80% of surgeons were aware of current guidelines, 60% did not routinely give 3 months of warfarin. In 
addition 60% of surgeons believed that antiplatelet therapy is an acceptable alternative to warfarin and over 60% 
of surgeons thought that warfarin was no longer the standard of care for tissue aortic valves. In 2005 Vaughan 
and Waterworth [4] surveyed UK consultant surgeons and found that 53% never use warfarin for tissue aortic 
valves, and 33% do not anticoagulate tissue mitral valve replacements. Only 16% of surgeons followed ACCP 
guidelines. 
Turning to the original papers, most recently Sundt et al. [111] from the Mayo clinic published in 2005 a 
retrospective practice review of 1151 patients undergoing tissue AVR, half of whom were anticoagulated. In the 
90 days after surgery 2.4% who were anticoagulated had a stroke compared to 1.9% of patients who were not 
anticoagulated. There was no difference in bleeding rates or reopening rates. They conclude that while they 
showed no significant benefit, they also showed no harm due to bleeding rates and acknowledged the 
underpowered nature of their study. Gherli et al. in 2004 [112] found no significant difference in stroke rate after 
tissue AVR between 108 patients who had warfarin (eight strokes) and 148 patients who had aspirin (four 
strokes). There was also no difference in bleeding rates. The authors advocated aspirin only after tissue AVR. 
Much of the evidence quoted by the ACCP guidelines derives from a 1995 report from the Mayo Clinic by Heras 
et al. [113]. They quote a rate of thromboembolic events of 50 per 100 patient-year (%py) in the first 10 days 
after tissue AVR without warfarin but none with warfarin. In tissue MVR the event rate of 2.5% py with 
warfarin was significantly lower than 3.9% py without warfarin. However, the validity of the data pertaining to 
AVR has been called into question by authors from the same institution. Sundt et al. [111] stated that of the 424 
patients who had a tissue AVR only five patients had a thromboembolic event in the first 10 days, and thereafter 
none of the AVR data demonstrated a significant difference. 
Moinuddeen et al. [114] reported in a cohort study of 185 patients that the rate of stroke or transient ischaemic 
event (TIA) was 18% in both the aspirin and warfarin groups after a mean 5-year follow-up. The bleeding rate 
was not significantly different. They concluded that warfarin was not required for AVR although again this study 
is too small to exclude a benefit for warfarin in this situation. 
Mistiaen et al. [115] in 2004 analysed 500 elderly patients receiving a Carpentier-Edwards pericardial valve and 
found on multivariate analysis that use of warfarin actually increased the risk of thromboembolism with a risk 
ratio of 3.0 after 4-year follow-up. While this was a study of 500 patients, only 30 patients in sinus rhythm 
actually received long-term warfarin to form this high-risk group, of whom 7 had a stroke. 
Yao et al. [116] in 2003 reported that the 10-year freedom from thromboembolism after tissue MVR was 100% 
with long-term anticoagulation but only 71% if anticoagulation was not given. However, there were only 22 
patients in the anticoagulation group. 
The ACCP guidelines quote the paper by Turpie et al. [117] from 1988 to demonstrate that 5% (2/40) of patients 
with an INR = 2.5—4.0 and 5.1% (2/39) with an INR= 2.0—2.3 had a thromboembolic event after tissue MVR, 
but the bleeding rate was lower in the low INR group. This paper did not have a 'no-anticoagulation' arm and 
was not powered to detect a significant difference. The study by lonescu et al. from 1982 [118] is also quoted as 
evidence in favour of anticoagulation for tissue MVR. In this 1971-1981 series, 5.9% (4/68) who did not receive 
anticoagulants and none of 182 patients who received warfarin had an ischaemic event during the first 3 months. 
Nowell et al. published a high-quality systematic review on antithrombotic therapy after tissue aortic valve 
replacement [108] in 2007, summarising 28 papers and highlighting the weaknesses of the current 
recommendations for warfarin. The recommendation for long-term antiplatelet therapy was also questioned as 
the evidence for this is also lacking, although guidelines are unanimous in their support for this therapy 
[119,120]. 
Further data may be available in the next few years from two registries that are in the early stages of data 
collection. The ANSWER registry (ANticoagulation Strategy With tissue valves: ostoperative Event Registry) 
intends to collect data on 2000 American patients who receive a Biocor™ or Biocor Supra™ valve either in the 
aortic or mitral position. Data on anticoagulation therapy will be collected and follow-up will be at 3 and 6 
months and consists of telephone interviews (personal communication from Duke Clinical Research Institute). 
The second registry includes 45 centres and is called the ACTION registry (Anti Coagulation Treatment 
Influence On Postoperative patients). This will collect data on tissue aortic valves and has already reported initial 
survey results indicating a widely varying practice [121]. 
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Recommendation: 
After tissue aortic valve replacement and in the absence of other indications for anticoagulation, antiplatelet 
therapy alone is adequate. Most guidelines recommend warfarin for 3 months after tissue mitral valve 
replacement. There is insufficient evidence to support or negate this recommendation. Patients who have an 
indication for anticoagulation such as atrial fibrillation should be anticoagulated. Anticoagulation for others is 
reasonably safe and may be beneficial. Antiplatelet therapy alone however is an acceptable alternative. (Grade B 
recommendation based on level 2b and 3b studies). 
8.2. Antiplatelets in addition to warfarin for patients with mechanical heart valves 
Evidence was sought for whether addition of antiplatelet therapy to warfarin reduced the incidence of 
thromboembolic complications in patients with mechanical heart valves. This search is fully documented in the 
ICVTS [122] together with a summary of all identified papers. Altogether 253 papers were found using the 
reported search, of which only 11 papers represented the best evidence to answer the clinical question. Despite 
this, 12 meta-analyses or current guidelines were also found, all of which consider the evidence either from these 
studies or from each other. 
Of the 11 trials, 6 used dipyridamole as an antiplatelet drug in doses of 225—400 mg once daily. Four trials used 
aspirin in doses of 500 mg once daily, 500 mg twice daily and in three recent trials, 100—200 mg once daily. 
The best metaanalyses were published by Massel and Little [123,124] and found that aspirin reduced the odds of 
all-cause mortality from 9% to 5.2%, which was significant. Breaking this down there was a significant 
reduction of thromboembolic events from 9% to 3.8% but with a corresponding increase in major bleeding from 
5.4% to 8.5% (all significant). Massel performed many sub-analyses and sensitivity analyses to see if the dose of 
aspirin, the date of the study, or the quality of study had an impact and found that the risk of bleeding appears to 
have diminished with the lower doses of aspirin used in the more recent trials. 
Of the 11 trials, only 3 investigate low-dose aspirin. Laffort et al. [125] performed a single blind RCT in 229 
patients comparing aspirin 200 mg with control with warfarin at an INR of 2.5—3.5. They found a significantly 
reduced level of thromboembolism but an increase in major bleeding. Turpie [120] performed a double-blind 
RCT in 370 patients using aspirin 100 mg with warfarin at an INR of 3.0—4.5. All-cause mortality was reduced 
from 12% to 4.8%, with significant reductions in thromboembolism but with a nonsignificant rise in major 
bleeding. Meschengieser et al. [126] performed a RCT in 503 patients which studied aspirin (100 mg) in 
combination with low dose warfarin (INR of 2.5— 3.5) to high dose warfarin alone (INR of 3.5—4.5). They 
found a trend towards more major bleeding and all major events in the warfarin only group and the rate of 
thromboembolism were similar. 
Of the clinical guidelines, the American Heart Association recommends that aspirin 80—100 mg should be 
strongly considered unless contraindicated with level 2a evidence. The European Society of Cardiology 2005 
guidelines [6] are more conservative due to concerns over bleeding complications. They recommend antiplatelet 
agents in addition to warfarin only for patients with concomitant arterial disease, previous stenting, pulmonary 
embolism or high-risk valve implants. The British committee for standards in haematol-ogy makes no 
recommendation for addition of aspirin but SIGN recommend aspirin for any patients who also suffer systemic 
embolism despite adequate anticoagulation. The ACCP recommend aspirin in addition to anticoagulation but 
acknowledge the increased risk of bleeding, giving this grade 1 status. The Massel meta-analysis finds that 
aspirin addition reduces the risk of all-cause mortality with a number needed to treat of 19. Most guidelines 
recommend addition of aspirin to warfarin but a survey of cardiac surgeons' opinion in North America and 
Canada showed that cardiac surgeons very much under-prescribe additional aspirin for fear of the increased risk 
of bleeding despite these guidelines. 
Recommendation: 
Low dose aspirin (80—100 mg daily) in addition to warfarin in patients with mechanical heart valves reduces 
all-cause mortality (NNT = 19), with significant reductions in thromboembolism but with more bleeding 
complications. (Grade A recommendation based on level 1a and 1b studies) 
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8.3. Warfarin anticoagulation for 3 months after mitral valve repair 
Evidence was sought for whether oral anticoagulants are necessary after mitral valve repair with or without an 
annuloplasty ring. This search is fully documented in the ICVTS [127] together with a summary of all identified 
papers. Altogether 127 papers were found using the reported search, of which 12 papers represented the best 
evidence to answer the clinical question. 
The 2006 ACC/AHA guidelines [27] for the management of patients with heart valve disease do not provide 
recommendations for patients who have undergone a mitral valve repair and neither do the ACCP guidelines of 
2004 [30]. The European Society of Cardiology provides guidelines for these patients, stating that there are no 
RCTs to support the safety of omitting warfarin after mitral repair. They recommend 3 months of warfarin at a 
target INR of 2.5 or 3.0 if there are additional risk factors. They acknowledge that this is based on expert 
consensus and acknowledge that many surgeons do not follow this guideline. 
Mitral valve repair is now recognised as the gold standard for mitral regurgitation. Around 70% of all procedures 
on the mitral valve are repair with or without an annuloplasty ring. AF is a common postoperative arrhythmia 
and is more common after mitral valve surgery than after any other open-heart procedure. Thus while a mitral 
valve repair may potentially be the least pro-thrombotic treatment among valve procedures the prevalence of AF 
in these patients may be an indication for anticoagulation. 
The thromboembolic rate is highest in the first 3 months after surgery. Around 20% of all thromboembolic 
complications occur during the first month, due to the hypercoagul-able state, which then decreases with time. 
The endothelialisation process of the newly implanted valve ring takes several weeks. The sewing valve ring, 
suture knots, atheromatous plaques, and calcium deposits on the dissected valve apparatus are prone to platelet 
deposition and thrombus formation when exposed to blood. The postoperative milieu after mitral repair is 
suggested to be similar to that after mitral bioprosthesis implant. 
Jovin et al. [128] reviewed 245 patients who underwent mitral repair for regurgitation from 1996 to 2001 and 
found 73 (29%) were admitted with AF, 65 (27%) left the hospital in AF and 64 (36%) had an episode of AF 
during the postoperative period. Of the 65 patients who were in AF at discharge, 61 (94%) were discharged on 
warfarin, 1 (1.5%) on warfarin and aspirin, 2 (3%) on aspirin and 1 (1.5%) received no anticoagulation at 
discharge. Of the 180 patients who were in sinus rhythm at discharge, 98 (54%) were discharged on warfarin, 78 
(43%) were discharged on aspirin and 3 (2%) received no anticoagulation or antiplatelet therapy at discharge. 
Jovin anticoagulated patients undergoing mitral repair for 3 months as recommended for mitral tissue valves. 
Aramendi et al. [129] studied 235 mitral surgery patients from 1990 to 1995 of whom 67 had repair and the rest 
tissue valves. Of the 209 survivors, 137 were assigned initially to receive ticlopidine (250 mg bd) for at least 3 
months postoperatively. The remainder were treated with aspirin, warfarin or neither. Mean follow-up was 3.2 
years and complete in 96% of 122 patients studied. AF was present in a greater proportion of the warfarin-treated 
group (50% vs 30%; p< 0.05). In total, six episodes of thromboembolism were reported. All occurred in the first 
postoperative year, four during the first 3 months, with the highest risk in the first month rapidly declining 
thereafter. There were four episodes of haemorrhage for the entire series, all in the first 3 months. Galloway [4] 
studied 148 patients after mitral repair and showed 95% 5-year freedom from thromboembolism without long-
term anticoagulant therapy. All patients were started on warfarin on the third postoperative day for 3 months. 
Incidence of anticoagulation-related complications was 0.33% py. One episode of bleeding was reported at 50 
months, six late thromboembolic complications were reported in five patients and one patient died from stroke. 
Freedom from late thromboembolism was 98% at 1 year and 95% for years 2—7. 
Deloche et al. [130] followed up 195 patients after mitral repair. All were started on warfarin on third 
postoperative day for 3 months, unless otherwise indicated. At 15 years, 10 patients had a thromboembolic 
event, for an actuarial freedom from thromboembolism of 94% ± 2.3% at 15 years. Of the 10 events, 7 were 
transient, 1 permanent and 1 fatal. 
Carpentier [131,132] has reported the longest follow-up of 928 patients with mitral repair up to 29 years. All had 
warfarin for 2 months. Only three patients had a stroke in the first 3 months. There were 37 thromboembolic 
events in these patients strongly associated with AF. 
In a survey [4] of cardiac surgeons in Great Britain, 64% use warfarin after mitral repair with an annuloplasty 
ring and 54% used only aspirin in the long-term. 
Published in: European Journal of Cardio - Thoracic Surgery (2008), vol.34, iss.1, pp. 73-92 
Status: Postprint (Author’s version) 
 
Recommendation: 
There is insufficient evidence on the need or safety of anticoagulation after mitral repair. Patients who have an 
indication for anticoagulation such as atrial fibrillation should be anticoagulated. Anticoagulation for others is 
reasonably safe and may be beneficial. Antiplatelet therapy alone is an acceptable alternative. (Grade C 
recommendation based on an absence of studies demonstrating the safety of omission and level 2b and 3b 
studies). 
9. Anticoagulation for patients with de novo AF after cardiac surgery 
This issue has been addressed in our previous guideline [133] and the recommendations are documented below 
Recommendation: 
After cardiac surgery, patients with AF should be anticoagulated with warfarin while in AF with a target INR of 
2—3, and full anticoagulation should be started within 48 h of the onset of AF due to a doubling of their risk of 
stroke. (Grade A recommendation based on level 1a studies) 
Immediate full anticoagulation in patients going into AF within 48 h of their operation is not supported due to 
the increased risk of cardiac tamponade. (Grade C recommendation based on an individual level 2b study) 
There is insufficient evidence to recommend whether patients who suffer an episode of AF after cardiac surgery 
but who return to sinus rhythm will benefit from a further 4—6 weeks of anticoagulation. (Grade E 
recommendation based on expert consensus) 
10. Heparin for thromboprophylaxis 
Evidence was sought for whether the use of prophylactic postoperative unfractionated or low molecular weight 
heparin (LMWH) after cardiac surgery would significantly reduce morbidity by reducing the incidence of deep 
vein thrombosis (DVT) and pulmonary embolism (PE). This search is fully documented in the ICVTS [134] 
together with a summary of identified papers. Relevant major guidelines were also searched together with their 
reference lists. Of 390 papers, 16 represented the best evidence on the topic. After this search, the National 
Institute for Health and Clinical Excellence also published extensive guidance in this area in 2007 and this is 
summarised below [135]. 
Shammas, [136] in a literature review to estimate the incidence of DVT and PE after cardiac surgery, identified 
eight studies comprising over 18,000 patients [137—144] and found that if routine ultrasound or venography 
was performed the incidence of DVT was 22%, and proximal DVT 15%. The incidence of PE was 0.8% and 
fatal PE 0.16%. Interestingly the clinical detection of DVT was less than 2% and half were in the non-harvested 
leg. 
Ambrosettia et al. in 2004 [145] performed serial ultrasound of 270 consecutive patients after CABG attending 
three rehabilitation programmes. The incidence of DVT was 17%, proximal DVT 2.6% and two patients suffered 
a PE. Half the DVTs were in non-harvested leg. 
The data were analysed for any protective effect of heparin but the findings were inconclusive. 
Ramos et al. in 1996 [146] performed a large RCT comparing subcutaneous heparin (5000 units bd) to heparin 
plus intermittent compression stockings. The incidence of PE decreased from 4% to 1.5% with this intervention. 
This study showed that even with good prophylaxis, the incidence of PE after cardiac surgery is around 3%. 
Considering whether prophylaxis significantly reduces the incidence of DVTand PE, we could find no clinical 
trials that assessed the impact of DVT prophylaxis in patients after cardiac surgery. However the ACCP [147] in 
2001 published a comprehensive systematic review and guideline on DVT prophylaxis in other specialties. In 
general surgery, 68 trials in nearly 20,000 patients have shown that either heparin or LMWH reduces the relative 
risk of DVT by 70%. In hip replacement surgery in over 40 trials with 7000 patients LMWH or heparin reduced 
the risk by up to 78%. Three ICU trials showed at least a halving of DVT, and three post-MI studies also showed 
a reduction. The general surgery trials have also demonstrated a reduction in proximal DVT, PE and fatal PE. 
Thus across the whole range of surgical and medical conditions the incidence of DVT is high and prophylaxis 
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significantly reduces the incidence of DVT and its sequelae. 
Gutt et al. in 2005 [148] performed a systematic review of DVT prophylaxis in general surgery and stated that 
LMWH at low doses reduced bleeding risk compared to heparin but the risk was higher with high doses. This 
risk was not quantified. In a systematic review of general surgery, Bergqvist in 2003 [149] concluded that the 
rate of bleeding with lower doses of LMWH was lower compared to unfractionated heparin, but this did rise as 
the dose increased. 
Malouf et al. [150] assessed 141 patients on warfarin after cardiac surgery with serial echocardiography. The 
incidence of large pericardial effusion was 4% in controls and 32% on warfarin, with 12 having delayed 
tamponade. As a caveat, 41 patients had excessive anticoagulation at some stage and this study was in patients 
receiving full warfarin anticoagulation rather than prophylactic heparin. 
Kulik et al. in 2006 [151] performed a systematic review of four early anticoagulation strategies after mechanical 
valve replacement (warfarin alone, with subcutaneous heparin, with LMWH and with intravenous heparin). The 
bleeding rate was highest with intravenous heparin at 8% and was lower with subcutaneous heparin or LMWH at 
around 4%. 
The National Institute of Health and Clinical Excellence [135] recommends that all patients undergoing cardiac 
surgery should be offered mechanical DVT prophylaxis and any patient with an additional risk factor should also 
receive LMWH. These risk factors include: age over 60, active heart failure, central venous catheter in situ, BMI 
>30, recent MI and immobility. Mechanical DVT prophylaxis was defined as thigh-length graduated 
compression/anti-embolism stockings, placed from the time of admission until that time at which they have 
regained their normal mobility. 
Recommendation: 
The incidence of thromboembolism after cardiac surgery is similar to the incidence in patients undergoing high-
risk general surgery. (Grade B recommendation based on level 2b studies) 
The ACCP guidelines recommend heparin prophylaxis for high-risk groups and NICE recommends low 
molecular weight heparin and mechanical deep vein thrombosis prophylaxis for virtually all patients undergoing 
cardiac surgery. 
After cardiac surgery, patients should receive mechanical deep vein thrombosis prophylaxis and low molecular 
weight heparin starting on the first postoperative day. (Grade B recommendation based on level 1b and 2b 
studies) 
11. Antiplatelet management for patients after cardiac surgery 
11.1. Dose of aspirin after coronary artery bypass grafting 
Evidence was sought for the optimal dose of aspirin for patients post-coronary artery bypass grafting. This 
search is fully documented in the ICVTS [152], together with a summary of all identified papers. Of 173 papers 
using the presented search strategy, 7 represented the best evidence on this topic. One additional paper has since 
been published and the ACCP and the Joint British Societies guidelines [153] have published relevant guidelines 
in this area. 
Fremes et al.'s meta-analysis [154] demonstrated a significant benefit of low and medium dose aspirin in 
comparison to high dose aspirin. The benefit of medium dose aspirin was greatest but confidence intervals 
overlap those for low dose aspirin. Neither the antiplatelet trial investigators nor the Veterans study group were 
able to convincingly demonstrate an advantage of medium dose aspirin in comparison to low dose aspirin. 
Mangano et al. [155] provided the first evidence for a convincing survival benefit from aspirin. However, the 
range of aspirin used was from 80 mg to 650 mg, so no evidence was provided for choosing a dose within this 
range. Of note there was no evidence of a higher rate of GI and bleeding complications in the non-aspirin group. 
Lim et al. [156] performed an indirect meta-analysis in 2003, where two RCTs of medium dose aspirin (300— 
325 mg) [157,158] were compared to three RCTs of low dose aspirin (75—150 mg) [159—161]. The medium 
dose trials yielded a relative risk reduction of 45% compared with 26% for the low dose trials. This gave a 
relative risk ratio of 0.74 (95% confidence interval 0.52—1.06; p = 0.10) for graft occlusion and 0.81               
Published in: European Journal of Cardio - Thoracic Surgery (2008), vol.34, iss.1, pp. 73-92 
Status: Postprint (Author’s version) 
 
(0.57—1.16; p = 0.25) for events in patients. Again while no statistically significant findings were reported to the 
p < 0.05 level, a trend towards benefit with medium dose aspirin was reported. 
In December 2005 the Joint British Societies guidelines on prevention of cardiovascular disease in clinical 
practice [153] published a comprehensive document on all aspects of secondary prevention in patients with 
cardiovascular disease. They recommend aspirin at a dose of 75—150mg for all patients 'at high risk' of 
suffering a cardiovascular event. They did not however consider CABG patients as a separate entity from general 
high-risk patients. 
In 2001 the 6th ACCP consensus conference on antithrombotic therapy [162] recommended 325 mg/day of 
aspirin, starting 6 h after surgery. However in the 2004 7th ACCP consensus conference [163], this 
recommendation was altered to 75—325 mg at 6 h and then 75—162 mg/day indefinitely. This was graded as 
1A evidence. 
Recommendation: 
Aspirin should be given postoperatively to all patients without contra-indications after coronary artery bypass 
grafting in order to improve the long-term patency of vein grafts. The dose given should be 150—325 mg. 
Studies show a trendtowards maximal benefit with 325 mg/day in the first year. 
(Grade A recommendation based on level 1a and 1b studies) 
There is no evidence to promote the use of aspirin after coronary artery bypass grafting to improve the patency 
of arterial grafts. However aspirin may be recommended on the basis of improved survival of patients in general 
who have atherosclerotic disease. (Grade E recommendation based on expert consensus) 
11.2. Timing of aspirin after coronary artery bypass grafting 
Evidence was sought for the optimal timing of the first dose of aspirin for patients after CABG. This search is 
fully documented in the ICVTS [164], together with a summary of all identified papers. We found 201 papers 
using the presented search strategy. From these papers, seven represented the best evidence on this topic. 
Fremes et al. [154] in a meta-analysis of 12 studies found that the benefit of aspirin was optimal if started at 6 h 
after surgery. In the individual studies, Gavaghan [157] showed the largest risk reduction when aspirin was given 
at 1 h after operation, but there was a non-significant increased rate of re-operation in this group. The study by 
Sharma et al. [165] showed that there was no benefit in giving aspirin if starting more than 48 h postoperatively. 
No significant increases in postoperative bleeding were shown in any studies. 
The 7th ACCP consensus conference on antithrombotic and thrombolytic therapy recommended 75—325 mg of 
aspirin 6 h after surgery, giving this a grade 1A recommendation [163]. 
Recommendation: 
Aspirin should be commenced within 24 h of coronary artery bypass grafting. (Grade A recommendation based 
on level 1a and 1b studies) 
There is a trend towards maximal benefit of aspirin the sooner it is given postoperatively. Giving aspirin at 6 h or 
when bleeding has ceased may therefore be the optimal strategy. (Grade B recommendation based on individual 
level 1a and 1b studies) 
 
11.3. Clopidogrel for the optimisation of graft patency 
Evidence was sought for whether clopidogrel should be given in addition to aspirin to high-risk patients after 
CABG to reduce thrombotic complications. This search is fully documented in the ICVTS [166,167], together 
with a summary of all identified papers. We found 511 papers using the presented search strategy. From these 
papers, 11 represented the best evidence on this topic. 
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The ACCP guidelines on clopidogrel [163] recommend that it should be started in addition to aspirin and 
continued for 9—12 months after CABG for non-ST segment elevation acute coronary syndrome. This 
recommendation is based on the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) 
study and the Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) study. 
CAPRIE reported an 8.7% relative risk reduction in the primary composite endpoint (first occurrence of 
ischaemic stroke, myocardial infarction or vascular death) in favour of clopidogrel (75 mg/day) over aspirin (325 
mg/day) in a multicentre RCT of 19,185 patients with a history of recent ischaemic stroke, recent MI or 
symptomatic peripheral arterial disease [168]. A sub-analysis of the CAPRIE database showed that in 1480 
patients with previous cardiac surgery, clopidogrel was associated with a relative risk reduction of 39% for 
vascular death, 38% for myocardial infarction, 25% for all-cause re-hospitalisa-tion, and 27% for re-
hospitalisation for ischaemia or bleeding. A major drawback of this study is the lack of information about the 
type of cardiac surgery previously performed. 
CURE randomised 12,562 patients with acute coronary syndromes to clopidogrel (300 mg then 75 mg/day) or 
placebo in addition to aspirin (75—325 mg/day). The antiplatelet combination resulted in a 20% risk reduction 
relative to aspirin alone (9.3% vs 11.4%, p < 0.001) in the primary endpoint of cardiovascular death, myocardial 
infarction or stroke over a mean 9-month treatment period [169]. The antiplatelet combination produced a 19% 
reduction relative to aspirin alone in the risk of cardiovascular death, myocardial infarction or stroke among 
those patients who underwent CABG surgery during the initial hospitalisation and an 11.0% relative risk 
reduction among patients who underwent CABG at any time during the treatment period. The clinical benefits of 
aspirin plus clopidogrel were mainly evident during the preoperative period with 18% relative risk reductions in 
the primary endpoint seen before CABG surgery compared to 3% relative risk reduction following CABG 
surgery relative to aspirin alone [21]. 
The Clopidogrel for the Reduction of Events During Observation (CREDO) trial evaluated the short-term 
benefits of combined aspirin and clopidogrel pre-treatment and the long-term benefits of sustained therapy in the 
setting of percutaneous coronary intervention (PCI) in an RCT of 2116 patients. After 1 year, patients receiving 
clopidogrel (75 mg/day) plus aspirin (81—325 mg/day) had a significant 26.9% relative risk reduction in the 
combined endpoint of death, myocardial infarction or stroke [22]. A subgroup analysis of patients who 
underwent CABG without PCI had a modest reduction of 1-year events (RRR 16.7%) with clopidogrel [170]. 
But this was a post-hoc analysis and the number of patients in this group was small. 
The recent observational study by Gurbuz et al. [171] showed that adding clopidogrel to aspirin was 
independently associated with decreased symptom recurrence and adverse cardiac events following off-pump 
CABG. However, extending clopidogrel use beyond 30 days did not have a significant effect on defined end 
points. 
In order to provide convincing evidence for clopidogrel and aspirin versus aspirin alone on saphenous vein graft 
disease after CABG, a double-blind RCT is currently underway. The CASCADE (Clopidogrel After Surgery for 
Coronary Artery Disease) is randomising 100 CABG patients to clopidogrel or placebo in addition to 162 mg of 
aspirin with 1-year angiography as the primary outcome measure [172]. This is due to report in 2008. 
With regard to the other high-risk group of patients, namely patients having CABG after PCI, we found no 
studies that looked at the outcome of stent patency after CABG. The ACCP guidelines [173] recommend 
clopidogrel in addition to aspirin for all patients after PCI for 9—12 months (grade 1A). A small study by 
Kaluza et al. [174] demonstrated that there was an in-stent thrombosis rate of around 20% with a similar 
mortality in patients having surgery of any type shortly after PCI. Therefore if the stented vessel is not grafted 
then it would seem reasonable to follow the ACCP guideline with 9—12 months of clopidogrel. However if the 
stent is covered by a graft more distally, there is no evidence to support continuation of clopidogrel. 
 
Recommendation: 
Clopidogrel (75 mg) is an acceptable alternative to aspirin for the optimisation of graft patency after coronary 
artery bypass grafting. (Grade B recommendation based on individual level 1b studies) 
The superiority of clopidogrel over aspirin for optimising graft patency after coronary artery bypass grafting has 
not yet been established and thus aspirin should be regarded as the drug of first choice. 
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(Grade B recommendation based on individual level 1b studies) 
In patients having cardiac surgery for acute coronary syndrome, clopidogrel should be considered for 9—12 
months in addition to aspirin. (Grade B recommendation based on sub-analyses of level 1 b studies) 
Clopidogrel may further improve the patency of saphenousvein grafts when given in additionto aspirin, but this 
will be at the expense of an increase in bleeding complications. (Grade B recommendation based on individual 
level 1a and 1b studies) 
In patients having coronary bypass surgery with a coronary stent in situ, clopidogrel should be continued if the 
stented vessel has not been grafted. (Grade E  recommendation  based on expert consensus) 
 
Acknowledgements 
The EACTS Audit and Guideline Committee is grateful to the following authors for assisting with the literature 
review process by publishing Best Evidence Topics for the ICVTS: Munir Amanullah, Sanjay Asopa, Khairul 
Anuar Abdul Aziz, Kunadian Babu, Victoria Close, Phil Botha, Satish Das, Moataz El-Husseiny, Mohammed 
Hanif, Andreas Hoschtitzky, Steven Hunter, Maninder Kalkat, Adrian Levine, Philip S. Lewis, Darbhamulla V. 
Nagarajan, Seyed Mahmoud Nouraei, Omar Masood, Kenneth Edward McLaughlin, Ghassan Musleh, Manoj 
Purohit, Shahzad G. Raja, Andrew Ronald, Kareem Salhiyyah, Marios Tanos, Sundaramoorthi 
Thiagarajamurthy, Andrew Thornley. 
References 
[1] Keogh BE, Kinsman R. Fifth National Audit Cardiac Surgical Database Report. The Society of Cardiothoracic Surgeons of Great Britain 
and Ireland, Published by Dendrite Clinical Systems Ltd.; 2003. 
[2] Graves EJ. National hospital discharge survey: annual summary, 1991. Vital Health Stat 1993;13:1-62.  
[3] Department of Health. Update on precautions to protect blood supply. Department of Health Publications and Statistics 2004; Reference 
number: 2004/0270.  
[4] Vaughan P, Waterworth PD. An audit of anticoagulation practice among UK cardiothoracic consultant surgeons following valve 
replacement/ repair. J Heart Valve Dis 2005;14(5):576-82.  
[5] Cardiothoracic Surgery Network (CTS-net) Valve technology center. Anticoagulation therapy after aortic Tissue valve replacement. 6/3/ 
2004 © CTSNet 2004.  
[6] Butchart EG, Gohlke-Barwolf C, Antunes MJ, Tornos P, De Caterina R, Cormier B, Prendergast B, Lung B, Bjornstad H, Leport C, Hall 
RJ, Vahanian A, Working Groups on Valvular Heart Disease, Thrombosis, and Cardiac Rehabilitation and Exercise Physiology, European 
Society of Cardiology. Recommendations for the management of patients after heart valve surgery. Eur Heart J 2005;26:2463-71.  
[7] Vahanian A, Baumgartner H, Bax J, Butchart EG, Dion R, Filippatos G, Flachskampf F, Lung B, Kasprzak J, Nataf P, Tornao P, 
Torracca L, Wenink A. Guidelines on the management of valvular heart disease: the Task Force on the Management of Valvular Heart 
Disease of The European Society of Cardiology. Eur Heart J 2007;28:230-69.  
[8] Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Ferraris SP, Saha SP, Hessel EA, Haan CK, 
Royston BD, Bridges CR, Higgins RS, DespotisG, Brown JR, Society of Cardiovascular Anesthesiologists Special Task Force on Blood 
Transfusion, Spiess BD, Shore-Lesserson L, Stafford-Smith M, Mazer CD, nett-Guerrero E, Hill SE, Body S. Perioperative blood transfusion 
and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical 
practice guideline. Ann Thorac Surg 2007;83 (5 Suppl.):S27-86.  
[9] Dunning J, Prendergast B, Mackway-Jones K. Towards evidence-based medicine in cardiothoracic surgery:  best BETS.  Interact 
Cardiovasc Thorac Surg 2003;2:405-9. 
[10] Strauss SE, Richardson WS, Glasziou P, Haynes RB. Evidence-based medicine: how to practice and teach EBM, 3rd ed., Edinburgh: 
Churchill Livingstone; 2005. 
[11] Kunadian B, Thornley AR, Tanos M, Dunning J. Should Clopidogrel be stopped prior to urgent cardiac surgery? Interact Cardiovasc 
Thorac Surg 2006;5:630-6. 
[12] Purkayastha S, Athanasiou T, Malinovski V, Tekkis P, Foale R, Casula R, Glenville B, Darzi A. Does clopidogrel affect outcome after 
coronary artery bypass grafting? A meta-analysis.   Heart 2006;92(4):531-2. 
Published in: European Journal of Cardio - Thoracic Surgery (2008), vol.34, iss.1, pp. 73-92 
Status: Postprint (Author’s version) 
 
[13] Kapetanakis El, Medlam DA, Petro KR, Haile E, Hill PC, Dullum MK, Bafi AS, Boyce SW, Corso PJ. Effect of clopidogrel 
premedication in off-pump cardiac surgery: are we forfeiting the benefits of reduced hemorrhagic sequelae? Circulation 2006;113(13):1667-
74. 
[14] Kapetanakis El, Medlam DA, Boyce SW, Haile E, Hill PC, Dullum MK, Bafi AS, Petro KR, Corso PJ. Clopidogrel administration prior 
to coronary artery bypass grafting surgery: the cardiologist's panacea or the surgeon's headache? Eur Heart J 2005;26(6):576-83. 
[15] Yende S, Wunderink RG. Effect of clopidogrel on bleeding after coronary artery bypass surgery. Crit Care Med 2001;29(12):2271-5. 
[16] Hongo RH, Ley J, Dick SE, Yee RR. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass 
grafting. J Am Coll Cardiol 2002;40(2):231-7. 
[17] Englberger L, Faeh B, Berdat PA, Eberli F, Meier B, Carrel T. Impact of clopidogrel in coronary artery bypass grafting. Eur J 
Cardiothorac Surg 2004;26(1):96-101. 
[18] Leong JY, Baker RA, Shah PJ, Cherian VK, Knight JL. Clopidogrel and bleeding after coronary artery bypass graft surgery. Ann 
Thorac Surg 2005;80(3):928-33. 
[19] Ascione R, Ghosh A, Rogers C, Cohen A, Monk C, Angelini GD. In hospital patients exposed to clopidogrel before coronary artery 
bypass graft surgery: a word of caution. Ann Thorac Surg 2005;79:1210-6. 
[20] Karabulut H, Toraman F, Evrenkaya S, Goksel  O, Tarcan S, Alhan C. Clopidogrel does not increase bleeding and allogeneic blood 
transfusion in coronary artery surgery. Eur J Cardiothorac Surg 2004;25(3): 419-23. 
[21 ] Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, Yusuf S. Benefits and risks of the combination of clopidogrel and aspirin in 
patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent 
Recurrent ischemic Events (CURE) Trial. Circulation 2004;110(10):1202-8. 
[22] Steinhubl SR, Berger PB, Mann III JT, Fry ET, DeLago A, Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy 
following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288(19):2411-20. 
[23] Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon J, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe 
CH, Braunwald E. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J 
Med 2005;352(12): 1179-89. 
[24] Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, 
Pepine CJ, Schaeffer JW, Smith III EE, Steward DE, Theroux P, Gibbons RJ, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, 
Jacobs AK, Smith Jr SC. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on 
the Management of Patients With Unstable Angina). ACC/AHA guideline update for the management of patients with unstable angina and 
non-ST-segment elevation myocardial infarction-2002: summary article: a report of the American College of Cardiology/American Heart 
Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 
2002;106(14):1893-900. 
[25] Mehta SR, Yusuf S, Peters R, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H-J, Zhao F, Chrolavicius S, Copland I, 
Fox KA. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary 
intervention: the PCI-CURE study. Lancet 2001;358:527-33. 
[26] Bonow RO, Carabello B, de Leon AC, Edmunds Jr LH, Fedderly BJ, Freed MD, Gaasch WH, McKay CR, Nishimura RA, O'Gara PT, 
O'Rourke RA, Rahimtoola SH, Ritchie JL, Cheitlin MD, Eagle KA, Gardner TJ, Garson Jr A, Gibbons RJ, Russell RO, Ryan TJ, Smith Jr 
SC. ACC/AHA Guidelines for the Management of Patients With Valvular Heart Disease. Executive Summary. A report of the American 
College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With 
Valvular Heart Disease). J Heart Valve Dis 1998;7(6):672-707. 
[27] Bonow RO, Carabello BA, Kanu C, de Jr LA, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, 
Otto CM, Shah PM, Shanewise JS, Smith Jr SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Faxon DP, Fuster V, Halperin JL, 
Hiratzka LF, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B, ACC/AHA Task Force, Society of Cardiovascular Anesthesiologists, 
Society for Cardiovascular Angiography, Interventions, Society of Thoracic Surgeons. ACC/AHA 2006 guidelines for the management of 
patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice 
Guidelines. Circulation 2006;114(5):e84-231. 
[28] Baglin TP, Keeling DM, Watson HG, For the British Committee for Standards in Haematology. Guidelines on oral anticoagulation 
(warfarin): third edition 2005 update. British Society for Haematology 2005;132: 277-85. 
[29] British Society of Haematologists. Guidelines on oral anticoagulation: third edition. British Journal of Haematology 1998; 101 
(374):387. 
[30] Salem DN, Stein PD, Al-Ahmad A, Bussey HI, Horstkotte D, Miller N, Pauker SG. Antithrombotic therapy in valvular heart disease—
native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3 Suppl.):457S-82S. 
 
 
Published in: European Journal of Cardio - Thoracic Surgery (2008), vol.34, iss.1, pp. 73-92 
Status: Postprint (Author’s version) 
 
[31 ] Eagle KA, Guyton RA, Davidoff R, Edwards FH, Ewy GA, Gardner TJ, Hart JC, Herrmann HC, Hillis LD, Hutter Jr AM, Lytle BW, 
Marlow RA, Nugent WC, Orszulak TA, Antman EM, Smith Jr SC, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, 
Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Ornato JP, American College of Cardiology/American Heart Association Task Force on 
Practice Guidelines Committee to Update the, American Society for Thoracic Surgery, Society of Thoracic Surgeons. ACC/AHA 2004 
guideline update for coronary artery bypass graft surgery: summary article. A report of the American College of Cardiology/American Heart 
Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). J Am 
Coll Cardiol 2004;44(5):e213-310. 
[32] Sethi GK, Copeland JG, Goldman S, Moritz T, Zadina K, Henderson WG. Implications of preoperative administration of aspirin in 
patients undergoing coronary artery bypass grafting: Department of Veterans Affairs Cooperative Study on Antiplatelet Therapy. J Am Coll 
Cardiol 1990;15:15-20. 
[33] Kalkat M, Levine A, Dunning J. Does use of aprotinin in coronary artery bypass graft surgery affect graft patency? Interact Cardiovasc 
Thorac Surg 2004;1(1):124-8. 
[34] Brown JR, Birkmeyer JD, O'Connor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in 
cardiac surgery. Circulation 2007;115:2801-13. 
[35] Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354:353-65. 
[36] Mangano DT, Miao Y, Vuylsteke A, Tudor IC, Juneja R, Filioescu D, Hoeft A, Fontes ML, Hillel Z, Ott E, Titov T, Dietzel C, Levin J. 
Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007;297(5):471-9. 
[37] International Standard Randomised Controlled Trial Number Register: registered number. ISRCTN15166455 2007. 
[38] U.S. Food and Drugs Administration Department of Health and Human Sciences. Early communication about an ongoing safety review 
aprotinin injection (marketed as Trasylol). Issued November 5, 2007. 
[39] Alderman EL, Levy JH, Rich JB, Nili M, Vidne B, Schaff H, Uretzky G, Pettersson G, Thiis JJ, Hantler CB, Chaitman B, Nadel A. 
Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience 
(IMAGE) trial. J Thorac Cardiovasc Surg 1998;116(5):716-30. 
[40] Laub GW, Riebman JB, Chen C, Adkins MS, Anderson WA, Fernandez J, McGrath LB. The impact of aprotinin on coronary artery 
bypass graft patency. Chest 1994; 106(5): 1370-5. 
[41] Lemmer Jr JH, Stanford W, Bonney SL, Breen JF, Chomka EV, Eldredge WJ, Holt WW, Karp RB, Laub GW, Lipton MJ. Aprotinin for 
coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, 
placebo-controlled study. J Thorac Cardiovasc Surg 1994; 107(2): 543-51. 
[42] Bidstrup BP, Underwood SR, Sapsford RN, Streets EM. Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency. J Thorac 
Cardiovasc Surg 1993;105(1):147-52. 
[43] van der Meer J, Hillege HL, Ascoop CA, Dunselman PH, Mulder BJ, van Ommen GV, Pfisterer M, van Gilst WH, Lie Kl. Aprotinin in 
aortocoronary bypass surgery: increased risk of vein-graft occlusion and myocardial infarction? Supportive evidence from a retrospective 
study. Thromb Haemost 1996;75(1):1-3. 
[44] Henry DA, Moxey AJ, Carless PA, O'Connell D, McClelland B, Henderson KM, Sly K, Laupacis A, Fergusson D. Anti-fibrinolytic use 
for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2003 (1). 
[45] Brown JR, Birkmeyer NJ, O'Connor GT. Aprotinin in cardiac surgery. N Engl J Med 354(18): 1953-7. 
[46] Munoz JJ, Birkmeyer NJ, Birkmeyer JD, O'Connor GT, Dacey LJ. Is epsilon-aminocaproic acid as effective as aprotinin in reducing 
bleeding with cardiac surgery? A meta-analysis.   Circulation 1999;99:81-9. 
[47] Mannucci PM, Levi M. Prevention and treatment of major blood loss. New Engl J Med 2007;356(22):2301-11. 
[48] Thiagarajamurthy S, Levine A, Dunning J. Does prophylactic tranexamic acid safely reduce bleeding without increasing thrombotic 
complications in patients undergoing cardiac surgery? Interact Cardiovasc Thorac Surg 2004;(3):489-94. 
[49] Fremes SE, Wong Bl, Lee E, Mai R, Christakis GT, McLean RF, Goldman BS, Naylor CD. Metaanalysis of prophylactic drug treatment 
in the prevention of postoperative bleeding. Ann Thorac Surg 1994;58(6): 1580-8. 
[50] Ovrum E, Am HE, Abdelnoor M, Oystese R, Ringdal ML. Tranexamic acid (Cyklokapron) is not necessary to reduce blood loss after 
coronary artery bypass operations. J Thorac Cardiovasc Surg 1993;105(1):78-83. 
[51] Casati V, Gerli C, Franco A, Torri G, D'Angelo A, Benussi S, Alfieri 0. Tranexamic acid in off-pump coronary surgery: a preliminary, 
randomized, double-blind, placebo-controlled study. Ann Thorac Surg 2001;72(2):470-5. 
[52] Hanif M, NoureiSM, DunningJ. Does the use of topical tranexamic acid in cardiac surgery reduce the incidence of post-operative 
mediastinal bleeding? Interact Cardiovasc Thorac Surg 2004;(4):603-5. 
Published in: European Journal of Cardio - Thoracic Surgery (2008), vol.34, iss.1, pp. 73-92 
Status: Postprint (Author’s version) 
 
[53] Baric D, Unie D, Rudez I, Sef D, Ivkovic M, Brkic K, Suttlic ZBB. Topical use of antifibrinolytic agents reduces postoperative 
bleeding: a double-blind prospective, randomised study. 5th EACTS/ESTS joint meeting content of scientific sessions 201-O. Interact 
Cardiovasc Thorac Surg 2006;5:S1-75. 
[54] Abdul-Azm A, Abdullah KM. Effect of topical tranexamic acid in open heart surgery. Eur J Anaesthesiol 2006;23(5):380-4. 
[55] Yasim A, Aik R, Atahan E. Effects of topical applications of aprotinin and tranexamic acid on blood loss after open heart surgery. 
Anadolu Kar-diyoloji Dergisi 2005;5(1):36-40. 
[56] De Bonis M, Cavaliere F, Alessandrini F, Lapenna E, Santarelli F, Moscato U, Schivello R, Possati GF. Topical use of tranexamic acid 
in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study. J Thorac Cardiovasc Surg 
2000;119:575-80. 
[57] Aziz KAA, Masood 0, Hoschtitzky A, Ronald A. Does use of the Hepcon point-of-care coagulation monitor to optimise heparin and 
protamine dosage for cardiopulmonary bypass decrease bleeding and blood and blood product requirements in adult patients undergoing 
cardiac surgery? Interact Cardiovasc Thorac Surg 2006;5:469-82. 
[58] Raymond PD, Ray MJ, Callen SN, Marsh NA. Heparin monitoring during cardiac surgery. Part 1 : validation of whole blood heparin 
concentration and activated clotting time. Perfusion 2003;18:269-76. 
[59] Murray DJ, Brosnahan WJ, Pennell B, Kapalanski D, Weiler JM, Olson J. Heparin detection by the activated coagulation time: a 
comparison of the sensitivity of coagulation tests and heparin assays. J Cardiothorac Vasc Anesth 1997;11:24-8. 
[60] Yamanishi H, Watanabe S, Hayashi K, Tomioka H, Minami M, Nozaki Y, Aoki T, Kawai Y, Kishino K, Ohta S. A clinical evaluation 
of the Hepcon/ HMS: a new device of monitoring hemostasis management during cardiopulmonary bypass. Kyobu Geka—Jpn J Thorac Surg 
1997;50:459-62. 
[61] Shigeta O, Kojima H, Hiramatsu Y, Jikuya T, Terada Y, Atsumi N, Sakakibara Y, Nagasawa T, Mitsui T. Low-dose protamine based on 
heparin-protamine titration method reduces platelet dysfunction after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1999;118: 354-60. 
[62] Despotis GJ, Joist JH, Hogue Jr CW, Alsoufiev A, Kater K, Goodnough LT, Santoro SA, Spitznagel E, Rosenblum M, Lappas DG. The 
impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in 
patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1995;110:46-54. 
[63] Despotis GJ, Joist JH, Hogue Jr CW, Alsoufiev A, Joiner-Maier D, Santoro SA, Spitznagel E, Weitz Jl, Goodnough LT. More effective 
suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations 
rather than ACT. Thromb Haemost 1996;76:902-8. 
[64] Newsome J, Stipanovich K, Flaherty S. Comparison of heparin administration using the Rapidpoint Coag and Hepcon HMS. J Extra-
Corporeal Technol 2004;36:139-44. 
[65] Sakurada T, Kikuchi Y, Koushima R, Nakashima S, Hachiro Y, Kagaya H. Clinical evaluation of heparin concentration and activated 
clotting time monitoring (HEPCON HMS) system. Nippon Kyobu Geka Gakkai Zasshi—J Jpn Assoc Thorac Surg 1997;45:836-40. 
[66] Beholz S, Grubitzsch H, Bergmann B, Wollert H-G, Eckel L. Haemostasis management by use of the Hepcony HMS: increased 
bleeding without increased need for blood transfusion. Thorac Cardiovasc Surgeon 1999;47:322-7. 
[67] Ohata T, Sawa Y, Ohtake S, Nishimura M, Chan CJ, Suzuki K, Matsuda H. Clinical role of blood heparin level monitoring during open 
heart surgery. Nihon Kyobu Geka Gakkai Zasshi—Jpn J Thorac Cardiovasc Surg 1999;47:600-6. 
[68] Koster A, Fischer T, Praus M, Haberzettl H, KueblerWM, Hetzer R, Kuppe H. Hemostatic activation and inflammatory response during 
cardiopulmonary bypass: impact of heparin management. Anesthesiology 2002;97: 837-41. 
[69] Avidan MS, Alcock EL, Da Fonseca J, Ponte J, Desai JB, Despotis GJ, Hunt BJ. Comparison of structured use of routine laboratory 
tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery. Br J Anaesth 2004;92:178-86. 
[70] Shore-Lesserson L, Reich DL, DePerio M. Heparin and protamine titration do not improve haemostasis in cardiac surgical patients. Can 
J Anaesth 1998;45:10-8. 
[71] Ronald A, Dunning J. Can the use of thromboelastography predict and decrease bleeding and blood and blood product requirements in 
adult patients undergoing cardiac surgery? Interact Cardiovasc Thorac Surg 2005;1(5):456-63. 
[72] Speiss BD, Tuman KJ, McCarthy RJ, DeLaria GA, Schillo R, Ivankovich AD. Thromboelastography as an indicator of post-
cardiopulmonary bypass coagulopathies. J Clin Monit 1987;3:25-30. 
[73] Ereth MH, Nuttall GA, Klindworth JT, MacVeigh I, Santrach PJ, Orszulak TA, Harmsen WS, Oliver WCJ. Does the platelet-activated 
clotting test (HemoSTATUS) predict blood loss and platelet dysfunction associated with cardiopulmonary bypass? Anesth Analg 
1997;85:259-64. 
[74] Essell JH, Martin TJ, Salinas J, Thompson JM, Smith JC. Comparison of thromboelastography to bleeding time and standard 
coagulation tests in patients after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1993;7:410-5. 
Published in: European Journal of Cardio - Thoracic Surgery (2008), vol.34, iss.1, pp. 73-92 
Status: Postprint (Author’s version) 
 
[75] Ti LK, Cheong KF, Chen FG. Prediction of excessive bleeding after coronary artery bypass graft surgery: the influence of timing and 
heparinase on thromboelastography. J Cardiothorac Vasc Anesth 2002;16:545-50. 
[76] Nuttall GA, Oliver WC, Ereth MH, Santrach PJ. Coagulation tests predict bleeding after cardiopulmonary bypass. J Cardiothorac Vasc 
Anesth 1997;11:815-23. 
[77] Dorman BH, Spinale FG, Bailey MK, Kratz JM, Roy RC. Identification of patients at risk for excessive blood loss during coronary 
artery bypass surgery: thromboelastography versus coagulation screen. Anesth Analg 1993;76(4):694-700. 
[78] Speiss BD, Gillies BS, Chandler W, Verrier E. Changes in transfusion therapy and re-exploration rate after institution of a blood 
management program in cardiac surgical patients. J Cardiothorac Vasc Anesth 1995;9:168-73. 
[79] Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F, Ergin MA. Thromboelastography-guided transfusion 
algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999;88:312-9. 
[80] Royston D, Von Kier S. Reduced haemostatic factor transfusion using heparinase-modified thrombelastography during cardiopulmonary 
bypass. Br J Anaesth 2001;86:575-8. 
[81 ] Samama CM, Ozier Y. Near-patient testing of haemostasis in the operating theatre: an approach to appropriate use of blood in surgery. 
Vox Sang 2003;84:251-5. 
[82] Mclaughlin KE, Dunning J. In patients post cardiac surgery do high doses of protamine cause increased bleeding? Interact Cardiovasc 
Thorac Surg 2003;(4):424-6. 
[83] Carr Jr ME, Carr SL. At high heparin concentrations, protamine concentrations which reverse heparin anticoagulant effects are 
insufficient to reverse heparin anti-platelet effects. Thromb Res 1994;75(6): 617-30. 
[84] Mochizuki T, Olson PJ, Szlam F, Ramsay JG, Levy JH. Protamine reversal of heparin affects platelet aggregation and activated clotting 
time after cardiopulmonary bypass. Anesth Analg 1998;87(4):781-5. 
[85] Butterworth J, Yonggu AL, Prielipp RC, Bennett J, Hammon JW, James RL. Rapid disappearance of protamine in adults undergoing 
cardiac operation with cardiopulmonary bypass. Ann Thorac Surg 2002;74:1589-95. 
[86] Gundry SR, Drongowski RA, Klein MD, Coran AG. Postoperative bleeding in cardiovascular surgery. Does heparin rebound really 
exist? Am Surg 1989;55(3):162-5. 
[87] Jobes DR, Aitken GL, Shaffer GW. Increased accuracy and precision of heparin and protamine dosing reduces blood loss and 
transfusion in patients undergoing primary cardiac operations. J Thorac Cardiovasc Surg 1995;110(1):36-45. 
[88] Tanos M, Dunning J. Is recombinant activated factor VII useful for intractable bleeding after cardiac surgery? Interact Cardiovasc 
Thorac Surg 2006;5:493-8. 
[89] Roberts HR, Monroe III DM, Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol 2004;41(1 Suppl. 1):101   8. 
[90] Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VI la for treatment of severe bleeding: a systematic review. Crit 
Care Med 2005;33(4):883-90. 
[91 ] Boffard KD, Riou B, Warren B, Choong PI, Rizoli S, Rossaint R, Axelsen M, Kluger Y, NovoSeven Trauma Study Group. 
Recombinant factor Vila as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-
controlled, double-blind clinical trials. J Trauma 2005;59(1):8-15. 
[92] Diprose P, Herbertson MJ, O'Shaughnessy D, Gill RS. Activated recombinant factor VII after cardiopulmonary bypass reduces 
allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth 
2005;95(5):596-602. 
[93] Herbertson M. Recombinant activated factor VII in cardiac surgery. Blood Coagul Fibrinolysis 2004;5(Suppl. 1):S31-2. 
[94] Karkouti K, Beattie WS, Wijeysundera DN, Yau TM, McCluskey SA, Ghannam M, Sutton D, van RA, Karski J. Recombinant factor 
Vila for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion 2005;45(1):26-34. 
[95] Aggarwal A, Malkovska V, Catlett JP, Alcorn K. Recombinant activated factor VII (rFVIIa) as salvage treatment for intractable 
hemorrhage. Thrombosis J 2004;2(1):9. 
[96] von Heymann C, Redlich U, Jain U, Kastrup M, Schroeder T, Sander M, Grosse J, Ziemer S, Koscielny J, Konertz WF, Wernecke KD, 
Spies C. Recombinant activated factor VII for refractory bleeding after cardiac surgery—a retrospective analysis of safety and efficacy. Crit 
Care Med 2005;33(10):2241-6.  
[97] Hyllner M, Houltz E, Jeppsson A. Recombinant activated factor VII in the management of life-threatening bleeding in cardiac surgery. 
Eur J Cardiothorac Surg 2005;28(2):254-8.  
 
Published in: European Journal of Cardio - Thoracic Surgery (2008), vol.34, iss.1, pp. 73-92 
Status: Postprint (Author’s version) 
 
[98] Bishop CV, Renwick WEP, Hogan C, Haeusler M, Tuckfield A, Tatoulis J. Recombinant activated factor VII : treating postoperative 
hemorrhage in cardiac surgery. Ann Thorac Surg 2006;81:875-9.  
[99] Vanek T, Straka Z, Hrabak J, Jares M, Brucek PJ, Votava J. Use of recombinant activated factor VII in cardiac surgery for an effective 
treatment of severe intractable bleeding. Jpn Heart J 2004;45(5): 855-60. 
[100] Halkos ME, Levy JH, Chen E, Reddy VS, Lattouf OM, Guyton RA, Song HK. Early experience with activated recombinant factor VII 
for intractable hemorrhage after cardiovascular surgery. Ann Thorac Surg 2005;79(4): 1303-6. 
[101] Al Douri M, Shafi T, Al Khudairi D, Al Bokhari E, Black L, Akinwale N, Osman MM, Al Homaidhi A, Al Fagih M, Borum AR. 
Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in 
patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis 2000;11 (Suppl. 1):S121-7. 
[102] DiDomenico RJ, Massad MG, Kpodonu J, Navarro RA, Geha AS. Use of recombinant activated factor VII for bleeding following 
operations requiring cardiopulmonary bypass. Chest 2005; 127(5): 1828-35. 
[103] Jamieson WR, Cartier CP, Allard M. Surgical management of valvular heart disease. Can J Cardiol 2004;20(Suppl. E):7-120. 
[104] Lowe G, Belch J, Burton C, Cachia P, Coo kM, Cooke T, Forbes C, Greer I, Irving J, Ludlam C, MclnnesG, Murray P, Sandercock P, 
Treasure I, Walker I, Webster J. Antithrombotic Therapy. Scottish Intercollegiate Guidelines Network Royal College of Physicians of 
Edinburgh. SIGN Guideline Network; 1999. 
[105] Baudet EM, Puel V, McBride JT. Long-term results of valve replacement with the St. Jude Medical prosthesis. J Thorac Cardiovasc 
Surg 1995;109:858-70. 
[106] Gohlke-Barwolf C, Acar J, Oakley C, Butchart EG, Burkhardt D, Bodnar E, Hall R, Delahaye JP, Horstkotte D, Krayenbuhl HP, 
Krzeminska-Pakula M, Kremer R, Samama M. Guidelines for the prevention of thromboembolic events in valvular heart disease. Eur Heart J 
1995;16:1320-30. 
[107] El-Husseiny M, Salhiyyah K, Raja SG, Dunning J. Should warfarin be routinely prescribed for the first three months after a 
bioprosthetic valve replacement? Interact Cardiovasc Thorac Surg 2006;5:616-23. 
[108] Nowell J, Wilton E, Markus H, Jahangiri M. Antithrombotic therapy following bioprosthetic aortic valve replacement. Eur J 
Cardiothorac Surg 2007;(31):578-85. 
[109] Stein PD, Alpert JS, Bussey HI, Dalen JE, Turpie AG. Antithrombotic therapy in patients with mechanical and biological prosthetic 
heart valves. Chest 2001;119(1 Suppl.):220S-7S. 
[110] Bonow RO, Carabello B, de Jr LA, Edmunds Jr LH, Fedderly BJ, Freed MD, Gaasch WH, McKay CR, Nishimura RA, O'Gara PT, 
O'Rourke RA, Rahimtoola SH, Ritchie JL, Cheitlin MD, Eagle KA, Gardner TJ, Garson Jr A, Gibbons RJ, Russell RO, Ryan TJ, Smith Jr 
SC. Guidelines for the management of patients with valvular heart disease: executive summary. A report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart 
Disease). Circulation 1998;98(18): 1949-84. 
[111] Sundt TM, Zehr KJ, Dearani JA, Daly RC, Mullany CJ, McGregor CG, Puga FJ, Orszulak TA, Schaff HV. Is early anticoagulation 
with warfarin necessary after bioprosthetic aortic valve replacement? J Thorac Cardiovasc Surg 2005;129(5):1024-31. 
[112] Gherli T, Colli A, Fragnito C, Nicolini F, Borrello B, Saccani S, D'Amico R, Beghi C. Comparing warfarin with aspirin after biological 
aortic valve replacement: a prospective study. Circulation 2004; 110(5):496—500. 
[113] Heras M, Chesebro JH, Fuster V, Penny WJ, Grill DE, Bailey KR, Danielson GK, Orszulak TA, Pluth JR, Puga FJ, Schaff HV, 
Larsonkeller JJ. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol 1995;25(5):1111-9. 
[114] Moinuddeen K, Quin J, Shaw R, DewarM, Tellides G, Kopf G, Elefteriades J. Anticoagulation is unnecessary after biological aortic 
valve replacement. Circulation 1998;98(19 Suppl.):ll95-8. 
[115] Mistiaen W, Van CP, Muylaert P, Sys SU, Harrisson F, Bortier H. Thromboembolic events after aortic valve replacement in elderly 
patients with a Carpentier-Edwards Perimount pericardial bioprosthesis. J Thorac Cardiovasc Surg 2004;127(4):1166-70. 
[116] Yao H, Miyamoto T, Mukai S, Yamamura M, Tanaka H, Nakagawa T, Ryomoto M, Inai Y, Yoshioka Y, Kaji M. Long-term results of 
mitral valve replacement: biological xenograft versus mechanical valves. J Artif Organs 2003;6:30-6. 
[117] Turpie AG, Gent M, Laupacis A, Latour Y, Gunstensen J, Basile F, Klimek M, Hirsh J. A comparison of aspirin with placebo in 
patients treated with warfarin after heart-valve replacement. N Engl J Med 1993;329(8): 524-9. 
[118] lonescu Ml, Smith DR, Hasan SS, Chidambaram M, Tandon AP. Clinical durability of the pericardial xenograft valve: ten years 
experience with mitral replacement. Ann Thorac Surg 1982;34(3):265—77. 
[119] Nowell J, Jahangiri M. Antiplatelet therapy after bioprosthetic aortic valve replacement is unnecessary in patients without 
thromboembolic risk. Eur J Cardiothorac Surg 2007;32:945. 
Published in: European Journal of Cardio - Thoracic Surgery (2008), vol.34, iss.1, pp. 73-92 
Status: Postprint (Author’s version) 
 
[120] BrueckM, Kramer W, Vogt P, Steinert N, Roth R, Gorlach G, Schonburg M, Heidt MC. Antiplatelet therapy early after bioprosthetic 
aortic valve replacement is unnecessary in patients without thromboembolic risk factors. Eur J Cardiothorac Surg 2007;32:108-12. 
[121] Colli A, Verhoye J-P, Robin H, Strauch J, Matt P, Pagano D. Anticoagulation Therapy After Bioprosthetic Aortic Valve Replacement: 
Action Registry Survey Results. Society for Heart Valve disease: fourth biennial meeting, New York, USA; 2007. p. 52. 
[122] Nagarajan DV, Lewis PS, Botha P, Dunning J. Is addition of anti-platelet therapy to warfarin beneficial to patients with prosthetic heart 
valves? Interact Cardiovasc Thorac Surg 2004;(3):450-5. 
[123] Massel D, Little SH. Risks and benefits of adding anti-platelet therapy to warfarin among patients with prosthetic heart valves: a meta-
analysis. J Am Coll Cardiol 2001;37(2):569-78. 
[124] Little SH, Massel D. Antiplatelet and anticoagulation for patients with prosthetic heart valves. The Cochrane Library, vol. 1, 2003. 
[125] Laffort P, Roudaut R, Roques X, Lafitte S, Deville C, Bonnet J, Baudet E. Early and long-term (one-year) effects of the association of 
aspirin and oral anticoagulant on thrombi and morbidity after replacement of the mitral valve with the St. Jude medical prosthesis: a clinical 
and transesophageal echocardiographic study. J Am Coll Cardiol 2000;35(3): 739-46. 
[126] Meschengieser SS, Fondevila CG, Frontroth J, Santarelli MT, Lazzari MA. Low-intensity oral anticoagulation plus low-dose aspirin 
versus high-intensity oral anticoagulation alone: a randomized trial in patients with mechanical prosthetic heart valves. J Thorac Cardiovasc 
Surg 1997;113(5):910-6. 
[127] Asopa S, Patel A, Dunning J. Is short term anticoagulation necessary after mitral valve repair? Interactive J Thorac Cardiovasc Surg 
2006;5:761-5. 
[128] Jovin A, Hashim S, Jovin IS, Clancy JF, Klovekorn WP, Muller-Berghaus G. Atrial fibrillation at discharge from the hospital in 
patients undergoing mitral valve repair. Thorac Cardiovasc Surg 2005;53(1):41-5. 
[129] Aramendi JL, Agredo J, Llorente A, Larrarte C, Pijoan J. Prevention of thromboembolism with ticlopidine shortly after valve repair or 
replacement with a bioprosthesis. J Heart Valve Dis 1998;7(6):610-4. 
[130] Deloche A, Jebara VA, Relland JY, Chauvaud S, Fabiani JN, Perier P, Dreyfus G, Mihaileanu S, Carpentier A. Valve repair with 
Carpentier techniques. The second decade. J Thorac Cardiovasc Surg 1990;99(6): 990-1001. 
[131] Braunberger E, Deloche A, Berrebi A, Abdallah F, Celestin JA, Meimoun P, Chatellier G, Chauvaud S, Fabiani JN, Carpentier A. Very 
long-term results (more than 20 years) of valve repair with Carpentier's techniques in nonrheumatic mitral valve insufficiency. Circulation 
2001 ; 104(90001 ): 81-111. 
[132] Chauvaud S, Fuzellier JF, Berrebi A, Deloche A, Fabiani JN, Carpentier A. Long-term (29 years) results of reconstructive surgery in 
rheumatic mitral valve insufficiency. Circulation 2001; 104(90001): 121-51. 
[133] Dunning J, Treasure T, Versteegh M, Nashef SAM. Guidelines on the prevention and management of de novo atrial fibrillation after 
cardiac and thoracic surgery. Eur J Cardiothorac Surg 2006;30:852-72. 
[134] Close V, Purohit M, Tanos M, Hunter S. Should patients post cardiac surgery be given low molecular weight heparin for deep vein 
thrombosis prophylaxis? Interact Cardiovasc Thorac Surg 2006;5:624-9. 
[135] The National Collaborating Centre for Acute Care. Venous thromboembolism: reducing the risk of venous thromboembolism (deep 
vein thrombosis and pulmonary embolism) in inpatients undergoing surgery, NICE clinical guideline 46. National Institute for Health and 
Clinical Excellence, 71 High Holborn, London, UK, 2007. 
[136] Shammas NW. Pulmonary embolus after coronary artery bypass surgery: a review of the literature. Clin Cardiol 2000;23(9):637-44. 
[137] Reis SE, Polak JF, Hirsch DR, Cohn LH, Creager MA, Donovan BC, Gold-haber SZ. Frequency of deep venous thrombosis in 
asymptomatic patients with coronary artery bypass grafts. Am Heart J 1991;122(2): 478-82. 
[138] Josa M, Siouffi SY, Silverman AB, Barsamian EM, Khuri SF, Sharma GV. Pulmonary embolism after cardiac surgery. J Am Coll 
Cardiol 1993;21 (4): 990-6. 
[139] GoldhaberSZ, Hirsch DR, MacDougall RC, Polak JF, Creager MA, Cohn LH. Prevention of venous thrombosis after coronary artery 
bypass surgery (a randomized trial comparing two mechanical prophylaxis strategies). Am J Cardiol 1995;76(14):993-6. 
[140] DeLaria GA, Hunter JA. Deep venous thrombosis. Implications after open heart surgery. Chest 1991;99(2):284-8. 
[141] Wisoff BG, Hartstein ML, Aintablian A, Hamby Rl. Risk of coronary surgery. Two hundred consecutive patients with no hospital 
deaths. J Thorac Cardiovasc Surg 1975;69(5):669-73. 
[142] Rao G, Zikria EA, Miller WH, Samadani SR, Ford WB. Incidence and prevention of pulmonary embolism after coronary artery 
surgery. Vase Surg 1975;9(1):37-45. 
 
Published in: European Journal of Cardio - Thoracic Surgery (2008), vol.34, iss.1, pp. 73-92 
Status: Postprint (Author’s version) 
 
[143] Pouplard C,May MA, lochmann S, Amiral J, Vissac AM, Marchand M, Gruel Y. Antibodies to platelet factor 4-heparin after 
cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for 
heparin-induced thrombocytopenia. Circulation 1999;99(19):2530-6. 
[144] Gillinov AM, Davis EA, Alberg AJ, Rykiel M, Gardner TJ, Cameron DE. Pulmonary embolism in the cardiac surgical patient. Ann 
Thorac Surg 1992;53(6):988-91. 
[145] Ambrosetti M, Salerno M, Zambelli M,Mastropasqua F,Tramarin R, Pedretti RF. Deep vein thrombosis among patients entering 
cardiac rehabilitation after coronary artery bypass surgery. Chest 2004; 125(1 ):191- 6. 
[146] Ramos R, Salem Bl, DePawlikowski MP, Coordes C, Eisenberg S, Leidenfrost R. The efficacy of pneumatic compression stockings in 
the prevention of pulmonary embolism after cardiac surgery. Chest 1996; 109(1 ):82-5. 
[147] Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson Jr FA, Wheeler HB. Prevention of venous thromboembolism. 
Chest 2001 ;119(1 Suppl.):132S-75S. 
[148] Gutt CN, Oniu T, Wolkener F, Mehrabi A, Mistry S, Buchler MW. Prophylaxis and treatment of deep vein thrombosis in general 
surgery. Am J Surg 2005;89(1):14-22. 
[149] Bergqvist D. Low molecular weight heparin for the prevention of venous thromboembolism after abdominal surgery. Br J Surg 
2004;91(8): 965-74. 
[150] Malouf JF, Alam S, Gharzeddine W, Stefadouros MA. The role of anticoagulation in the development of pericardial effusion and late 
tamponade after cardiac surgery. Eur Heart J 1993;14(11 ): 1451-7. 
[151] Kulik A, Rubens FD, Wells PS, Kearon C, Mesana TG, van Berkom J, Lam BK. Early postoperative anticoagulation after mechanical 
valve replacement: a systematic review. Ann Thorac Surg 2006;81:700-81. 
[152] Dunning J, Das S. What is the optimal dose of aspirin after discharge following coronary bypass surgery. Interact Cardiovasc Thorac 
Surg 2003;(4):427-30. 
[153] British Cardiac Society, British Hypertension Society, Diabetes, U.K., HEART, U.K., Primary Care Cardiovascular Society, Stroke 
Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(Suppl. 
5):v1-52. 
[154] Fremes SE, Levinton C, Naylor CD, Chen E, Christakis GT, Goldman BS. Optimal antithrombotic therapy following aortocoronary 
bypass: a meta-analysis. Eur J Cardiothorac Surg 1993;7(4):169-80. 
[155] Mangano DT. Aspirin and mortality from coronary bypass surgery. New Engl J Med 2002;347(17):1309-17. 
[156] Lim E, Ali Z, Ali A, Routledge T, Edmonds L, Altman DG, Large S. Indirect comparison meta-analysis of aspirin therapy after 
coronary surgery. Br Med J 2003;327:1309-11. 
[157] Gavaghan TP, Gebski V, Baron DW. Immediate postoperative aspirin improves vein graft patency early and late after coronary artery 
bypass graft surgery: a placebo-controlled, randomized study. Circulation 1991;83(5):1526-33. 
[158] Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, Doherty J, Read R, Chesler E, Sako Y. Saphenous vein graft 
patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy. Results of a Veterans Administration Cooperative 
Study. Circulation 1989;80(5):1190-7. 
[159] Lorenz RL, Schacky CV, Weber M, Meiter W, Kotzur J, Reichardt B. Improved aortocoronary bypass patency by low-dose aspirin 
(100 mg daily). Effects on platelet aggregation and thromboxane formation). Lancet 1984;l(1261):1264. 
[160] Sanz G, Pajaron A, Alegria E, Coello I, Cardona M, Fournier JA, Gomez-Recio M, Ruano J, Hidalgo R, Medina A. Prevention of early 
aortocoronary bypass occlusion by low-dose aspirin and dipyridamole. Grupo Espanol para el Seguimiento del Injerto Coronario (GESIC). 
Circulation 1990;82(3):765-73. 
[161] Hockings BE, Ireland MA, Gotch-Martin KF, Taylor RR. Placebo-controlled trial of enteric coated aspirin in coronary bypass graft 
patients. Effect on graft patency. Med J Aust 1993; 159(6): 376-8. 
[162] Stein P, Dalen J, Goldman S, Theroux P. Antithrombotic therapy in patients with saphenous veins and internal mammary artery bypass 
grafts. Chest 2001 ;119(1 ):278S-82S. 
[163] Stein PD, Schunemann HJ, Dalen JE, Gutterman D. Antithrombotic therapy in patients with saphenous vein and internal mammary 
artery bypass grafts: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl.):600S-8S. 
[164] Musleh G, Dunning J. Does aspirin 6 h after coronary artery bypass grafting optimise graft patency? Interact Cardiovasc Thorac Surg 
2003;(4):413-5. 
[165] Sharma GV, Khuri SF, Josa M, Folland ED, Parisi AF. The effect of antiplatelet therapy on saphenous vein coronary artery bypass 
graft patency. Circulation 1983;68(3 Pt 2):t-21. 
Published in: European Journal of Cardio - Thoracic Surgery (2008), vol.34, iss.1, pp. 73-92 
Status: Postprint (Author’s version) 
 
[166] Kunadian B, Babu N, Dunning J. Should high risk patients receive clopidogrel as well as aspirin post coronary arterial bypass grafting? 
Interact Cardiovasc Thorac Surg 2006;5:755-60. 
[167] Nagarajan DV, Lewis PS, Dunning J. Is clopidogrel beneficial following coronary bypass surgery? Interact Cardiovasc Thorac Surg 
2004;(2): 311-3. 
[168] Bhatt DL, Chew DP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Superiority of clopidogrel versus aspirin in patients with prior 
cardiac surgery. Circulation 2001;103(3):363-8. 
[169] Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute 
coronary syndromes without ST-segment elevation. N Engl J Med 2001 ;345(7):494-502. 
[170] Saw J, Topol EJ, Steinhubl SR, Brennan D, Berger PB, Moliterno DJ, CREDO Investigators. Comparison of long-term usefulness of 
clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat 
intervention. Am J Cardiol 2004;94(5):623-5. 
[171] Gurbuz AT, Zia AA, Vuran AC, Cui H, Aytac A. Postoperative clopidogrel improves mid-term outcome after off-pump coronary 
artery bypass graft surgery: a prospective study. Eur J Cardiothorac Surg 2006; 29(2):190-5. 
172]. Kulik A, Le May M, Wells GA, Mesana TG, Ruel M. The clopidogrel after surgery for coronary artery disease (CASCADE) 
randomized controlled trial: clopidogrel and aspirin versus aspirin alone after coronary bypass surgery. Curr Control Trials Cardiovasc Med 
2005;6(15) [NCT00228423]. 
[173] Popma JJ, Berger P, Ohman EM, Harrington RA, Grines C, Weitz Jl. Antithrombotic therapy during percutaneous coronary 
intervention: Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:576-99. 
[174] Kaluza GL, Joseph J, Lee JR, Raizner ME, Raizner AE. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J 
Am Coll Cardiol 2000; 35(5): 1288-94. 
